The companion diagnostics market is projected to reachGreater thanGreater thanGreater thanGreater than USD 11.57 billion by 2031, fromGreater thanGreater thanGreater thanGreater than USD 6.31 billion in 2026, with a CAGR of 12.9%. This growth is primarily driven by increasing oncology biomarker testing, expanding approvals of targeted therapies and immunotherapies, and rising pharmaceutical-diagnostic co-development activities. Market growth is further supported by advancements in molecular diagnostics technologies, such as polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry, and in situ hybridization, along with increased demand for personalized treatment selection. However, high development and validation costs, complex regulatory pathways, reimbursement limitations, and variability in biomarker testing infrastructure across regions are expected to restrain market growth to a certain extent. ![Companion Diagnostics Market]( "Companion Diagnostics Market")
Assays, kits & reagents accounted for the largest share of the companion diagnostics market, by product & service, in 2025.
In 2025, assays, kits & reagents accounted for the largest share due to their extensive use in biomarker detection, mutation analysis, therapy selection, and routine molecular testing workflows. Their recurring demand, compatibility with high-throughput testing platforms, and increasing adoption in oncology-focused precision medicine applications continue to support segment growth. Additionally, rising approvals of companion diagnostic assays linked to targeted therapies and immunotherapies are further strengthening the dominance of this segment.PCR accounted for a major share of the companion diagnostics market, by technology, in 2025.
In 2025, PCR accounted for a major share due to its high analytical sensitivity, shorter turnaround time, broad clinical adoption, and strong regulatory acceptance in biomarker-driven testing. PCR technologies are widely used for mutation detection and targeted therapy selection across multiple oncology indications. Additionally, growing use of multiplex PCR assays and increasing demand for rapid molecular testing continue to support the segment’s leading market position globally.Asia Pacific is expected to be the fastest-growing market for companion diagnostics during the forecast period.
During the forecast period, the Asia Pacific region is projected to register the highest CAGR due to increasing cancer incidence, expanding healthcare infrastructure, rising investments in molecular diagnostics, and growing adoption of precision medicine approaches. Growth is further supported by improving access to advanced oncology care, expansion of pharmaceutical clinical trials, and increasing presence of regional and global diagnostic companies across China, Japan, India, South Korea, and Southeast Asia.Companies Profiled
- F. Hoffmann-La Roche AG
- Agilent Technologies, Inc
- Qiagen N.V.
- Thermo Fisher Scientific, Inc.
- Abbott Laboratories
- Almac Group
- Danaher Corporation
- Illumina Inc
- Biomerieux Sa
- Myriad Genetics, Inc
- Sysmex Corporation
- Guardant Health, Inc.
- Icon Plc
- Quest Diagnostics
- Amoy Diagnostics Co., Ltd
- Tempus Ai, Inc
- Caris Life Sciences, Inc.
Research Coverage
This research report categorizes the companion diagnostics market by product & service, technology, indication, sample, end user, drug class, application, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints, influencing the growth of the protein expression market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product portfolio, key strategies such as product and service approvals and launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the protein expression market. This report covers competitive analysis of top players and upcoming startups in the protein expression market ecosystem.Key Benefits of Buying this Report
The report will help market leaders and new entrants by providing the closest approximations of revenue numbers for the overall companion diagnostics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. The report will enable stakeholders to understand the market pulse and provide information on key market drivers, restraints, opportunities, and challenges.The report provides insights into the following points:
- Analysis of key drivers, including increasing adoption of precision medicine, expanding targeted therapy pipelines, rising oncology biomarker testing volumes, growing pharmaceutical-diagnostic partnerships, and increasing demand for personalized treatment approaches; restraints including high assay development costs, reimbursement limitations, and regulatory complexities; and challenges including standardization issues, biomarker validation complexities, and limited molecular testing infrastructure in emerging regions.
- Product Development/Innovation: Detailed insights on newly launched companion diagnostic assays, biomarker testing technologies, liquid biopsy platforms, NGS solutions, and therapy-linked molecular testing workflows.
- Market Development: Comprehensive information about lucrative markets - the report analyzes the companion diagnostics market across various regions.
- Market Diversification: Exhaustive information about product portfolios, technology developments, regulatory approvals, collaborations, partnerships, acquisitions, and investments in the companion diagnostics market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, technology capabilities, and service offerings of leading players such as F. Hoffmann-La Roche AG, Agilent Technologies, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Illumina Inc., bioMérieux SA, Sysmex Corporation, and Guardant Health, Inc.
Table of Contents
1 Introduction
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered & Regional Scope
1.3.2 Inclusions & Exclusions
1.3.3 Years Considered
1.3.4 Currency Considered
1.4 Stakeholders
1.5 Summary of Changes
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered & Regional Scope
1.3.2 Inclusions & Exclusions
1.3.3 Years Considered
1.3.4 Currency Considered
1.4 Stakeholders
1.5 Summary of Changes
2 Executive Summary
2.1 Key Insights & Market Highlights
2.2 Key Market Participants: Insights & Strategic Developments
2.3 Disruptive Trends Shaping Market Growth
2.4 High-Growth Segments & Emerging Frontiers
2.5 Snapshot: Global Market Size, Growth Rate, and Forecast
2.2 Key Market Participants: Insights & Strategic Developments
2.3 Disruptive Trends Shaping Market Growth
2.4 High-Growth Segments & Emerging Frontiers
2.5 Snapshot: Global Market Size, Growth Rate, and Forecast
3 Premium Insights
3.1 Companion Diagnostics Market Overview
3.2 Companion Diagnostics Market, by Product & Service, 2026 Vs. 2031
3.3 Companion Diagnostics Market, by Technology, 2026 Vs. 2031
3.4 Companion Diagnostics Market, by Indication, 2026 Vs. 2031
3.5 Companion Diagnostics Market, by Sample Type, 2026 Vs. 2031
3.6 Companion Diagnostics Market, by Drug Associated With Cdx, 2026 Vs. 2031
3.7 Companion Diagnostics Market, by Application, 2026 Vs. 2031
3.8 Companion Diagnostics Market: Geographic Growth Opportunities
3.2 Companion Diagnostics Market, by Product & Service, 2026 Vs. 2031
3.3 Companion Diagnostics Market, by Technology, 2026 Vs. 2031
3.4 Companion Diagnostics Market, by Indication, 2026 Vs. 2031
3.5 Companion Diagnostics Market, by Sample Type, 2026 Vs. 2031
3.6 Companion Diagnostics Market, by Drug Associated With Cdx, 2026 Vs. 2031
3.7 Companion Diagnostics Market, by Application, 2026 Vs. 2031
3.8 Companion Diagnostics Market: Geographic Growth Opportunities
4 Market Overview
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.1.1 Increasing Adoption of Precision Medicine and Targeted Therapies
4.2.1.2 Growing Investments in Genomics, Molecular Diagnostics, and Biomarker Discovery
4.2.1.3 Expanding Pharmaceutical-Diagnostic Co-Development Partnerships
4.2.2 Restraints
4.2.2.1 High Development, Clinical Validation, and Regulatory Approval Costs
4.2.3 Opportunities
4.2.3.1 Expansion of Liquid Biopsy and Non-Invasive Companion Diagnostics
4.2.3.2 AI-Driven Biomarker Interpretation and Digital Pathology Integration
4.2.4 Challenges
4.2.4.1 Regulatory Complexity Associated With Simultaneous Drug-Diagnostic Approvals
4.3 Unmet Needs & White Spaces
4.3.1 Unmet Needs in Companion Diagnostics Market
4.3.2 White Space Opportunities
4.4 Interconnected Markets & Cross-Sector Opportunities
4.4.1 Interconnected Markets
4.4.2 Cross-Sector Opportunities
4.5 Strategic Moves by Tier 1/2/3 Players
4.5.1 Key Moves & Strategic Focus
4.2 Market Dynamics
4.2.1 Drivers
4.2.1.1 Increasing Adoption of Precision Medicine and Targeted Therapies
4.2.1.2 Growing Investments in Genomics, Molecular Diagnostics, and Biomarker Discovery
4.2.1.3 Expanding Pharmaceutical-Diagnostic Co-Development Partnerships
4.2.2 Restraints
4.2.2.1 High Development, Clinical Validation, and Regulatory Approval Costs
4.2.3 Opportunities
4.2.3.1 Expansion of Liquid Biopsy and Non-Invasive Companion Diagnostics
4.2.3.2 AI-Driven Biomarker Interpretation and Digital Pathology Integration
4.2.4 Challenges
4.2.4.1 Regulatory Complexity Associated With Simultaneous Drug-Diagnostic Approvals
4.3 Unmet Needs & White Spaces
4.3.1 Unmet Needs in Companion Diagnostics Market
4.3.2 White Space Opportunities
4.4 Interconnected Markets & Cross-Sector Opportunities
4.4.1 Interconnected Markets
4.4.2 Cross-Sector Opportunities
4.5 Strategic Moves by Tier 1/2/3 Players
4.5.1 Key Moves & Strategic Focus
5 Industry Trends
5.1 Porter'S Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Competitive Rivalry
5.2 Macroeconomic Outlook
5.2.1 Introduction
5.2.2 GDP Trends & Forecast
5.2.3 Trends in Global Companion Diagnostics Industry
5.3 Supply Chain Analysis
5.4 Value Chain Analysis
5.5 Ecosystem Analysis
5.6 Pricing Analysis
5.6.1 Average Selling Price Trend, by Key Player, 2024-2026
5.6.2 Average Selling Price Trend, by Region, 2024-2026
5.6.3 Average Selling Price Trend, by Technology Type, 2024-2026
5.7 Trade Analysis
5.7.1 Import Scenario (Hs Code 3822)
5.7.2 Export Scenario (Hs Code 3822)
5.8 Key Conferences & Events, 2026-2027
5.9 Trends/Disruptions Impacting Customers’ Businesses
5.10 Investment & Funding Scenario
5.11 Impact of US Tariffs - Companion Diagnostics Market
5.11.1 Introduction
5.11.2 Key Tariff Rates
5.11.3 Price Impact Analysis
5.11.4 Impact On Countries/Regions
5.11.4.1 North America
5.11.4.2 Europe
5.11.4.3 Asia-Pacific
5.11.5 Impact On End-Use Industries
5.11.5.1 Hospital and Cancer Centers
5.11.5.2 Pharmaceutical and Biopharmaceutical Companies
5.11.5.3 Other End Users
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Competitive Rivalry
5.2 Macroeconomic Outlook
5.2.1 Introduction
5.2.2 GDP Trends & Forecast
5.2.3 Trends in Global Companion Diagnostics Industry
5.3 Supply Chain Analysis
5.4 Value Chain Analysis
5.5 Ecosystem Analysis
5.6 Pricing Analysis
5.6.1 Average Selling Price Trend, by Key Player, 2024-2026
5.6.2 Average Selling Price Trend, by Region, 2024-2026
5.6.3 Average Selling Price Trend, by Technology Type, 2024-2026
5.7 Trade Analysis
5.7.1 Import Scenario (Hs Code 3822)
5.7.2 Export Scenario (Hs Code 3822)
5.8 Key Conferences & Events, 2026-2027
5.9 Trends/Disruptions Impacting Customers’ Businesses
5.10 Investment & Funding Scenario
5.11 Impact of US Tariffs - Companion Diagnostics Market
5.11.1 Introduction
5.11.2 Key Tariff Rates
5.11.3 Price Impact Analysis
5.11.4 Impact On Countries/Regions
5.11.4.1 North America
5.11.4.2 Europe
5.11.4.3 Asia-Pacific
5.11.5 Impact On End-Use Industries
5.11.5.1 Hospital and Cancer Centers
5.11.5.2 Pharmaceutical and Biopharmaceutical Companies
5.11.5.3 Other End Users
6 Technological Advancements, AI-Driven Impact, Patents, Innovations, and Future Applications
6.1 Key Emerging Technologies
6.1.1 Next-Generation Sequencing (Ngs)-Based Comprehensive Genomic Profiling
6.1.2 Liquid Biopsy (Cfdna/Ctdna Testing)
6.2 Complementary Technologies
6.2.1 Bioinformatics & AI-Driven Clinical Interpretation
6.2.2 Multiplex Pcr/Qpcr Platforms
6.3 Adjacent Technologies
6.3.1 Digital Pathology & AI-Based Imaging
6.4 Technology/Product Roadmap
6.5 Patent Analysis
6.5.1 List of Major Patents
6.6 Future Applications
6.7 Impact of AI/Generative AI On Companion Diagnostics Market
6.7.1 Introduction
6.7.2 Top Use Cases & Market Potential
6.7.3 Key Companies Implementing AI
6.7.4 Future of AI
6.1.1 Next-Generation Sequencing (Ngs)-Based Comprehensive Genomic Profiling
6.1.2 Liquid Biopsy (Cfdna/Ctdna Testing)
6.2 Complementary Technologies
6.2.1 Bioinformatics & AI-Driven Clinical Interpretation
6.2.2 Multiplex Pcr/Qpcr Platforms
6.3 Adjacent Technologies
6.3.1 Digital Pathology & AI-Based Imaging
6.4 Technology/Product Roadmap
6.5 Patent Analysis
6.5.1 List of Major Patents
6.6 Future Applications
6.7 Impact of AI/Generative AI On Companion Diagnostics Market
6.7.1 Introduction
6.7.2 Top Use Cases & Market Potential
6.7.3 Key Companies Implementing AI
6.7.4 Future of AI
7 Regulatory Landscape and Sustainability Initiatives
7.1 Regional Regulations & Compliance
7.1.1 Regulatory Analysis
7.1.1.1 North America
7.1.1.1.1 US
7.1.1.1.2 Canada
7.1.1.2 Europe
7.1.1.2.1 Germany
7.1.1.2.2 UK
7.1.1.2.3 France
7.1.1.2.4 Italy
7.1.1.3 Asia-Pacific
7.1.1.3.1 China
7.1.1.3.2 Japan
7.1.1.3.3 India
7.1.1.3.4 Australia
7.1.1.4 Latin America
7.1.1.4.1 Brazil
7.1.1.4.2 Mexico
7.1.1.5 Middle East
7.1.1.5.1 Africa
7.1.2 Regulatory Bodies, Government Agencies, and Other Organizations
7.2 Sustainability Initiatives
7.2.1 Environmental Impact & Eco-Friendly Initiatives
7.2.1.1 Eco-Friendly Initiatives
7.2.2 Sustainability Impact & Regulatory Policy Initiatives
7.1.1 Regulatory Analysis
7.1.1.1 North America
7.1.1.1.1 US
7.1.1.1.2 Canada
7.1.1.2 Europe
7.1.1.2.1 Germany
7.1.1.2.2 UK
7.1.1.2.3 France
7.1.1.2.4 Italy
7.1.1.3 Asia-Pacific
7.1.1.3.1 China
7.1.1.3.2 Japan
7.1.1.3.3 India
7.1.1.3.4 Australia
7.1.1.4 Latin America
7.1.1.4.1 Brazil
7.1.1.4.2 Mexico
7.1.1.5 Middle East
7.1.1.5.1 Africa
7.1.2 Regulatory Bodies, Government Agencies, and Other Organizations
7.2 Sustainability Initiatives
7.2.1 Environmental Impact & Eco-Friendly Initiatives
7.2.1.1 Eco-Friendly Initiatives
7.2.2 Sustainability Impact & Regulatory Policy Initiatives
8 Customer Landscape & Buyer Behavior
8.1 Decision-Making Process
8.2 Buyer Stakeholders & Buying Evaluation Criteria
8.2.1 Key Stakeholders in Buying Process
8.2.2 Buying Criteria
8.3 Adoption Barriers & Internal Challenges
8.4 Unmet Needs in Various End-Use Industries
8.5 Market Profitability
8.5.1 Revenue Potential
8.5.2 Cost Dynamics
8.2 Buyer Stakeholders & Buying Evaluation Criteria
8.2.1 Key Stakeholders in Buying Process
8.2.2 Buying Criteria
8.3 Adoption Barriers & Internal Challenges
8.4 Unmet Needs in Various End-Use Industries
8.5 Market Profitability
8.5.1 Revenue Potential
8.5.2 Cost Dynamics
9 Companion Diagnostics Market, by Product & Service
9.1 Introduction
9.2 Assays, Kits, and Reagents
9.2.1 Increasing Routine Use of Biomarker-Based Testing For Targeted Therapy and Immunotherapy Selection
9.3 Instruments/Systems
9.3.1 Rising Adoption of Automated Molecular, Pathology, and Ngs Platforms to Support Standardized and Scalable Cdx Testing
9.4 Software & Services
9.4.1 Increasing Demand For High-Value Ngs Interpretation, Liquid Biopsy Services, Pharma Cdx Co-Development, and Clinically Actionable Reporting
9.2 Assays, Kits, and Reagents
9.2.1 Increasing Routine Use of Biomarker-Based Testing For Targeted Therapy and Immunotherapy Selection
9.3 Instruments/Systems
9.3.1 Rising Adoption of Automated Molecular, Pathology, and Ngs Platforms to Support Standardized and Scalable Cdx Testing
9.4 Software & Services
9.4.1 Increasing Demand For High-Value Ngs Interpretation, Liquid Biopsy Services, Pharma Cdx Co-Development, and Clinically Actionable Reporting
10 Companion Diagnostics Market, by Sample Type
10.1 Introduction
10.2 Tissue Samples
10.2.1 Continued Dominance of Tissue-Based Biomarker Testing in Oncology Treatment Selection
10.3 Blood Samples
10.3.1 Rapid Adoption of Liquid Biopsy and Circulating Tumor Dna-Based Companion Diagnostics to Drive Market
10.4 Other Sample Types
10.2 Tissue Samples
10.2.1 Continued Dominance of Tissue-Based Biomarker Testing in Oncology Treatment Selection
10.3 Blood Samples
10.3.1 Rapid Adoption of Liquid Biopsy and Circulating Tumor Dna-Based Companion Diagnostics to Drive Market
10.4 Other Sample Types
11 Companion Diagnostics Market, by Technology
11.1 Introduction
11.2 Polymerase Chain Reaction
11.2.1 Preference For Cost-Effective, Clinically Established Single-Gene/Hotspot Mutation Testing Drives Market
11.3 in Situ Hybridization
11.3.1 Need For Tissue-Based Detection of Gene Amplification, Rearrangements, and Expression-Linked Therapy Selection Drive Market
11.4 Next-Generation Sequencing
11.4.1 Growing Applications in Diagnosing Bacterial, Viral, Fungal, and Parasitic Infections to Drive Market
11.5 Immunohistochemistry
11.5.1 Strong Use of Tissue-Based Protein-Expression Testing For Immuno-Oncology and Targeted Therapy Selection
11.6 Other Technologies
11.2 Polymerase Chain Reaction
11.2.1 Preference For Cost-Effective, Clinically Established Single-Gene/Hotspot Mutation Testing Drives Market
11.3 in Situ Hybridization
11.3.1 Need For Tissue-Based Detection of Gene Amplification, Rearrangements, and Expression-Linked Therapy Selection Drive Market
11.4 Next-Generation Sequencing
11.4.1 Growing Applications in Diagnosing Bacterial, Viral, Fungal, and Parasitic Infections to Drive Market
11.5 Immunohistochemistry
11.5.1 Strong Use of Tissue-Based Protein-Expression Testing For Immuno-Oncology and Targeted Therapy Selection
11.6 Other Technologies
12 Companion Diagnostics Market, by Indication
12.1 Introduction
12.2 Cancer
12.2.1 Lung Cancer
12.2.1.1 Growing Demand For Effective Therapeutic Drugs to Increase Cdx Adoption
12.2.2 Breast Cancer
12.2.2.1 Wide Prevalence of Breast Cancer Among Women Contributes to the Large Market Size of the Segment
12.2.3 Leukemia & Lymphoma
12.2.3.1 Precision Profiling of Targeted Alterations in Hematologic Malignancies
12.2.4 Colorectal Cancer
12.2.4.1 Integration of Biomarker Testing For Targeted and Immunotherapy Selection
12.2.5 Melanoma
12.2.5.1 High Immunotherapy and Targeted Therapy Use Based On Molecular Status
12.2.6 Other Cancers
12.3 Neurological Diseases
12.3.1 Rising Burden of Neurodegenerative Diseases to Drive Market
12.4 Cardiovascular Diseases
12.4.1 Rising Global Incidence of Cardiovascular Patients to Expedite Growth
12.5 Infectious Diseases
12.5.1 Increasing Awareness of Targeted Therapies to Propel Segment Growth
12.6 Other Indications
12.2 Cancer
12.2.1 Lung Cancer
12.2.1.1 Growing Demand For Effective Therapeutic Drugs to Increase Cdx Adoption
12.2.2 Breast Cancer
12.2.2.1 Wide Prevalence of Breast Cancer Among Women Contributes to the Large Market Size of the Segment
12.2.3 Leukemia & Lymphoma
12.2.3.1 Precision Profiling of Targeted Alterations in Hematologic Malignancies
12.2.4 Colorectal Cancer
12.2.4.1 Integration of Biomarker Testing For Targeted and Immunotherapy Selection
12.2.5 Melanoma
12.2.5.1 High Immunotherapy and Targeted Therapy Use Based On Molecular Status
12.2.6 Other Cancers
12.3 Neurological Diseases
12.3.1 Rising Burden of Neurodegenerative Diseases to Drive Market
12.4 Cardiovascular Diseases
12.4.1 Rising Global Incidence of Cardiovascular Patients to Expedite Growth
12.5 Infectious Diseases
12.5.1 Increasing Awareness of Targeted Therapies to Propel Segment Growth
12.6 Other Indications
14 Companion Diagnostics Market, by Application
14.1 Introduction
14.2 Clinical Diagnostics
14.2.1 Increasing Use of Cdx Testing For Real-Time Therapy Selection in Oncology and Precision Medicine
14.3 Research Use
14.3.1 Rising Biomarker Discovery and Pharma-Led Drug-Diagnostic Co-Development Programs
14.2 Clinical Diagnostics
14.2.1 Increasing Use of Cdx Testing For Real-Time Therapy Selection in Oncology and Precision Medicine
14.3 Research Use
14.3.1 Rising Biomarker Discovery and Pharma-Led Drug-Diagnostic Co-Development Programs
15 Companion Diagnostics Market, by End User
15.1 Introduction
15.2 Pharmaceutical & Biopharmaceutical Companies
15.2.1 Rising Pharma-Led Drug-Diagnostic Co-Development For Targeted Therapies and Immunotherapies Drives Market
15.3 Reference Laboratories
15.3.1 Increasing Demand For Outsourced High-Complexity Molecular and Genomic Cdx Testing
15.4 Contract Research Organizations
15.4.1 Increasing Use of Biomarker-Driven Clinical Trials and Cdx-Enabled Drug Development Programs
15.5 Other End Users
15.2 Pharmaceutical & Biopharmaceutical Companies
15.2.1 Rising Pharma-Led Drug-Diagnostic Co-Development For Targeted Therapies and Immunotherapies Drives Market
15.3 Reference Laboratories
15.3.1 Increasing Demand For Outsourced High-Complexity Molecular and Genomic Cdx Testing
15.4 Contract Research Organizations
15.4.1 Increasing Use of Biomarker-Driven Clinical Trials and Cdx-Enabled Drug Development Programs
15.5 Other End Users
16 Companion Diagnostics Market, by Drug Class Associated With Cdx
16.1 Introduction
16.2 Monoclonal Antibodies
16.2.1 Rising Use of Biomarker-Guided Monoclonal Antibody Therapies in Oncology and Immuno-Oncology
16.3 Cell & Gene Therapy
16.3.1 Increasing Need For Genetic, Antigen, and Patient-Eligibility Testing in Advanced Personalized Therapies
16.2 Monoclonal Antibodies
16.2.1 Rising Use of Biomarker-Guided Monoclonal Antibody Therapies in Oncology and Immuno-Oncology
16.3 Cell & Gene Therapy
16.3.1 Increasing Need For Genetic, Antigen, and Patient-Eligibility Testing in Advanced Personalized Therapies
17 Companion Diagnostics Market, by Region
17.1 Introduction
17.2 North America
17.2.1 US
17.2.1.1 Presence of Advanced Healthcare Infrastructure to Augment Growth
17.2.2 Canada
17.2.2.1 Expanding Public Oncology Testing Infrastructure and Growing Biomarker-Based Cancer Care
17.3 Europe
17.3.1 Germany
17.3.1.1 Advanced Molecular Pathology Infrastructure and Strong Oncology Testing Adoption
17.3.2 UK
17.3.2.1 Nhs-Led Genomic Medicine Infrastructure and National Test Directory-Based Access
17.3.3 France
17.3.3.1 National Cancer Programs and Structured Molecular Oncology Networks
17.3.4 Italy
17.3.4.1 Expanding Molecular Oncology Adoption Across Regional Cancer Centers
17.3.5 Switzerland
17.3.5.1 High-Value Precision Medicine Environment and Strong Pharma-Diagnostics Presence
17.3.6 Spain
17.3.6.1 Increasing Adoption of Biomarker-Guided Oncology Across Public Hospital Networks
17.3.7 Rest of Europe
17.4 Asia-Pacific
17.4.1 China
17.4.1.1 Large Oncology Patient Pool and Rapid Expansion of Domestic Precision Medicine Infrastructure
17.4.2 Japan
17.4.2.1 Universal Healthcare Reimbursement Policy to Foster Growth
17.4.3 India
17.4.3.1 Increased Private and Public Investments to Bolster Growth
17.4.4 South Korea
17.4.4.1 Advanced Healthcare Infrastructure and Strong Adoption of Precision Oncology Technologies
17.4.5 Australia
17.4.5.1 Strong Oncology Care Infrastructure and High Biomarker Testing Need in Melanoma and Solid Tumors
17.4.6 Rest of Asia-Pacific
17.5 Latin America
17.5.1 Brazil
17.5.1.1 Largest Oncology Patient Pool in Latin America and Growing Adoption of Precision Oncology in Private Healthcare
17.5.2 Mexico
17.5.2.1 Expanding Oncology Care Networks and Increasing Use of Biomarker Testing in Urban Cancer Centers
17.5.3 Rest of Latin America
17.6 Middle East & Africa
17.6.1 GCC Countries
17.6.1.1 Growing Public Healthcare Funding to Drive Market
17.6.2 Rest of Middle East & Africa
17.2 North America
17.2.1 US
17.2.1.1 Presence of Advanced Healthcare Infrastructure to Augment Growth
17.2.2 Canada
17.2.2.1 Expanding Public Oncology Testing Infrastructure and Growing Biomarker-Based Cancer Care
17.3 Europe
17.3.1 Germany
17.3.1.1 Advanced Molecular Pathology Infrastructure and Strong Oncology Testing Adoption
17.3.2 UK
17.3.2.1 Nhs-Led Genomic Medicine Infrastructure and National Test Directory-Based Access
17.3.3 France
17.3.3.1 National Cancer Programs and Structured Molecular Oncology Networks
17.3.4 Italy
17.3.4.1 Expanding Molecular Oncology Adoption Across Regional Cancer Centers
17.3.5 Switzerland
17.3.5.1 High-Value Precision Medicine Environment and Strong Pharma-Diagnostics Presence
17.3.6 Spain
17.3.6.1 Increasing Adoption of Biomarker-Guided Oncology Across Public Hospital Networks
17.3.7 Rest of Europe
17.4 Asia-Pacific
17.4.1 China
17.4.1.1 Large Oncology Patient Pool and Rapid Expansion of Domestic Precision Medicine Infrastructure
17.4.2 Japan
17.4.2.1 Universal Healthcare Reimbursement Policy to Foster Growth
17.4.3 India
17.4.3.1 Increased Private and Public Investments to Bolster Growth
17.4.4 South Korea
17.4.4.1 Advanced Healthcare Infrastructure and Strong Adoption of Precision Oncology Technologies
17.4.5 Australia
17.4.5.1 Strong Oncology Care Infrastructure and High Biomarker Testing Need in Melanoma and Solid Tumors
17.4.6 Rest of Asia-Pacific
17.5 Latin America
17.5.1 Brazil
17.5.1.1 Largest Oncology Patient Pool in Latin America and Growing Adoption of Precision Oncology in Private Healthcare
17.5.2 Mexico
17.5.2.1 Expanding Oncology Care Networks and Increasing Use of Biomarker Testing in Urban Cancer Centers
17.5.3 Rest of Latin America
17.6 Middle East & Africa
17.6.1 GCC Countries
17.6.1.1 Growing Public Healthcare Funding to Drive Market
17.6.2 Rest of Middle East & Africa
18 Competitive Landscape
18.1 Introduction
18.2 Key Player Strategies/Right to Win
18.2.1 Overview of Strategies Deployed by Players in Companion Diagnostics Market
18.3 Revenue Analysis, 2023-2025
18.4 Market Share Analysis, 2025
18.4.1 Global Market Share Analysis, 2025
18.5 Company Evaluation Matrix: Key Players, 2025
18.5.1 Stars
18.5.2 Emerging Leaders
18.5.3 Pervasive Players
18.5.4 Participants
18.5.5 Company Footprint: Key Players, 2025
18.5.5.1 Company Footprint
18.5.5.2 Region Footprint
18.5.5.3 Product & Service Footprint
18.5.5.4 Indication Footprint
18.5.5.5 Technology Footprint
18.6 Company Evaluation Matrix: Startups/SMEs, 2025
18.6.1 Progressive Companies
18.6.2 Responsive Companies
18.6.3 Dynamic Companies
18.6.4 Starting Blocks
18.6.5 Company Evaluation Matrix: Startups/SMEs, 2025
18.6.5.1 Detailed List of Key Startups/SMEs
18.6.5.2 Competitive Benchmarking of Startups/SMEs
18.7 Company Valuation & Financial Metrics
18.7.1 Financial Metrics
18.7.2 Company Valuation
18.8 Brand/Product Comparison
18.9 Competitive Scenario
18.9.1 Product Launches & Approvals
18.9.2 Deals
18.9.3 Expansions
18.9.4 Other Developments
18.2 Key Player Strategies/Right to Win
18.2.1 Overview of Strategies Deployed by Players in Companion Diagnostics Market
18.3 Revenue Analysis, 2023-2025
18.4 Market Share Analysis, 2025
18.4.1 Global Market Share Analysis, 2025
18.5 Company Evaluation Matrix: Key Players, 2025
18.5.1 Stars
18.5.2 Emerging Leaders
18.5.3 Pervasive Players
18.5.4 Participants
18.5.5 Company Footprint: Key Players, 2025
18.5.5.1 Company Footprint
18.5.5.2 Region Footprint
18.5.5.3 Product & Service Footprint
18.5.5.4 Indication Footprint
18.5.5.5 Technology Footprint
18.6 Company Evaluation Matrix: Startups/SMEs, 2025
18.6.1 Progressive Companies
18.6.2 Responsive Companies
18.6.3 Dynamic Companies
18.6.4 Starting Blocks
18.6.5 Company Evaluation Matrix: Startups/SMEs, 2025
18.6.5.1 Detailed List of Key Startups/SMEs
18.6.5.2 Competitive Benchmarking of Startups/SMEs
18.7 Company Valuation & Financial Metrics
18.7.1 Financial Metrics
18.7.2 Company Valuation
18.8 Brand/Product Comparison
18.9 Competitive Scenario
18.9.1 Product Launches & Approvals
18.9.2 Deals
18.9.3 Expansions
18.9.4 Other Developments
19 Company Profiles
19.1 Key Players
19.1.1 F. Hoffmann-La Roche Ltd.
19.1.1.1 Business Overview
19.1.1.2 Products/Services/Solutions Offered
19.1.1.3 Recent Developments
19.1.1.3.1 Product Launches & Approvals
19.1.1.3.2 Deals
19.1.1.3.3 Expansions
19.1.1.4 Analyst's View
19.1.1.4.1 Key Strengths
19.1.1.4.2 Strategic Choices
19.1.1.4.3 Weaknesses & Competitive Threats
19.1.2 Agilent Technologies, Inc
19.1.2.1 Business Overview
19.1.2.2 Products/Services/Solutions Offered
19.1.2.3 Recent Developments
19.1.2.3.1 Product Launches & Approvals
19.1.2.3.2 Deals
19.1.2.4 Analyst's View
19.1.2.4.1 Key Strengths
19.1.2.4.2 Strategic Choices
19.1.2.4.3 Weaknesses & Competitive Threats
19.1.3 Qiagen
19.1.3.1 Business Overview
19.1.3.2 Products/Services/Solutions Offered
19.1.3.3 Recent Developments
19.1.3.3.1 Product Launches & Approvals
19.1.3.3.2 Deals
19.1.3.3.3 Expansions
19.1.3.4 Analyst's View
19.1.3.4.1 Key Strengths
19.1.3.4.2 Strategic Choices
19.1.3.4.3 Weaknesses & Competitive Threats
19.1.4 Thermo Fisher Scientific Inc.
19.1.4.1 Business Overview
19.1.4.2 Products/Services/Solutions Offered
19.1.4.3 Recent Developments
19.1.4.3.1 Product Launches
19.1.4.3.2 Deals
19.1.4.4 Analyst's View
19.1.4.4.1 Key Strengths
19.1.4.4.2 Strategic Choices
19.1.4.4.3 Weaknesses & Competitive Threats
19.1.5 Abbott
19.1.5.1 Business Overview
19.1.5.2 Products/Services/Solutions Offered
19.1.5.3 Recent Developments
19.1.5.3.1 Product Approvals
19.1.5.3.2 Deals
19.1.5.4 Analyst's View
19.1.5.4.1 Key Strengths
19.1.5.4.2 Strategic Choices
19.1.5.4.3 Weaknesses & Competitive Threats
19.1.6 Danaher
19.1.6.1 Business Overview
19.1.6.2 Products/Services/Solutions Offered
19.1.6.3 Recent Developments
19.1.6.3.1 Product Approvals
19.1.6.3.2 Deals
19.1.6.4 Analyst's View
19.1.6.4.1 Key Strengths
19.1.6.4.2 Strategic Choices
19.1.6.4.3 Weaknesses & Competitive Threats
19.1.7 Illumina, Inc.
19.1.7.1 Business Overview
19.1.7.2 Products/Services/Solutions Offered
19.1.7.3 Recent Developments
19.1.7.3.1 Product Launches & Approvals
19.1.7.3.2 Deals
19.1.8 Biomérieux
19.1.8.1 Business Overview
19.1.8.2 Products/Services/Solutions Offered
19.1.8.3 Recent Developments
19.1.8.3.1 Deals
19.1.9 Myriad Genetics, Inc.
19.1.9.1 Business Overview
19.1.9.2 Products/Services/Solutions Offered
19.1.9.3 Recent Developments
19.1.9.3.1 Product Launches & Approvals
19.1.9.3.2 Deals
19.1.10 Sysmex Corporation
19.1.10.1 Business Overview
19.1.10.2 Products/Services/Solutions Offered
19.1.10.3 Recent Developments
19.1.10.3.1 Deals
19.1.11 Quest Diagnostics
19.1.11.1 Business Overview
19.1.11.2 Products/Services/Solutions Offered
19.1.11.3 Recent Developments
19.1.11.3.1 Deals
19.1.12 Guardant Health
19.1.12.1 Business Overview
19.1.12.2 Products/Services/Solutions Offered
19.1.12.3 Recent Developments
19.1.12.3.1 Product Launches & Approvals
19.1.13 Icon PLC
19.1.13.1 Business Overview
19.1.13.2 Products/Services/Solutions Offered
19.1.14 Tempus AI, Inc.
19.1.14.1 Business Overview
19.1.14.2 Products/Services/Solutions Offered
19.1.14.3 Recent Developments
19.1.14.3.1 Deals
19.1.14.3.2 Other Developments
19.1.15 Caris Life Sciences, Inc.
19.1.15.1 Business Overview
19.1.15.2 Products/Services/Solutions Offered
19.1.15.3 Recent Developments
19.1.15.3.1 Product Launches & Approvals
19.2 Other Players
19.2.1 the Almac Group
19.2.2 Amoy Diagnostics Co. Ltd.
19.2.3 Arup Laboratories
19.2.4 Abnova Corporation
19.2.5 Invivoscribe, Inc.
19.2.6 Q² Solutions
19.2.7 Creative Biolabs
19.2.8 Pillar Biosciences
19.2.9 Entrogen, Inc.
19.2.10 Biocartis
19.1.1 F. Hoffmann-La Roche Ltd.
19.1.1.1 Business Overview
19.1.1.2 Products/Services/Solutions Offered
19.1.1.3 Recent Developments
19.1.1.3.1 Product Launches & Approvals
19.1.1.3.2 Deals
19.1.1.3.3 Expansions
19.1.1.4 Analyst's View
19.1.1.4.1 Key Strengths
19.1.1.4.2 Strategic Choices
19.1.1.4.3 Weaknesses & Competitive Threats
19.1.2 Agilent Technologies, Inc
19.1.2.1 Business Overview
19.1.2.2 Products/Services/Solutions Offered
19.1.2.3 Recent Developments
19.1.2.3.1 Product Launches & Approvals
19.1.2.3.2 Deals
19.1.2.4 Analyst's View
19.1.2.4.1 Key Strengths
19.1.2.4.2 Strategic Choices
19.1.2.4.3 Weaknesses & Competitive Threats
19.1.3 Qiagen
19.1.3.1 Business Overview
19.1.3.2 Products/Services/Solutions Offered
19.1.3.3 Recent Developments
19.1.3.3.1 Product Launches & Approvals
19.1.3.3.2 Deals
19.1.3.3.3 Expansions
19.1.3.4 Analyst's View
19.1.3.4.1 Key Strengths
19.1.3.4.2 Strategic Choices
19.1.3.4.3 Weaknesses & Competitive Threats
19.1.4 Thermo Fisher Scientific Inc.
19.1.4.1 Business Overview
19.1.4.2 Products/Services/Solutions Offered
19.1.4.3 Recent Developments
19.1.4.3.1 Product Launches
19.1.4.3.2 Deals
19.1.4.4 Analyst's View
19.1.4.4.1 Key Strengths
19.1.4.4.2 Strategic Choices
19.1.4.4.3 Weaknesses & Competitive Threats
19.1.5 Abbott
19.1.5.1 Business Overview
19.1.5.2 Products/Services/Solutions Offered
19.1.5.3 Recent Developments
19.1.5.3.1 Product Approvals
19.1.5.3.2 Deals
19.1.5.4 Analyst's View
19.1.5.4.1 Key Strengths
19.1.5.4.2 Strategic Choices
19.1.5.4.3 Weaknesses & Competitive Threats
19.1.6 Danaher
19.1.6.1 Business Overview
19.1.6.2 Products/Services/Solutions Offered
19.1.6.3 Recent Developments
19.1.6.3.1 Product Approvals
19.1.6.3.2 Deals
19.1.6.4 Analyst's View
19.1.6.4.1 Key Strengths
19.1.6.4.2 Strategic Choices
19.1.6.4.3 Weaknesses & Competitive Threats
19.1.7 Illumina, Inc.
19.1.7.1 Business Overview
19.1.7.2 Products/Services/Solutions Offered
19.1.7.3 Recent Developments
19.1.7.3.1 Product Launches & Approvals
19.1.7.3.2 Deals
19.1.8 Biomérieux
19.1.8.1 Business Overview
19.1.8.2 Products/Services/Solutions Offered
19.1.8.3 Recent Developments
19.1.8.3.1 Deals
19.1.9 Myriad Genetics, Inc.
19.1.9.1 Business Overview
19.1.9.2 Products/Services/Solutions Offered
19.1.9.3 Recent Developments
19.1.9.3.1 Product Launches & Approvals
19.1.9.3.2 Deals
19.1.10 Sysmex Corporation
19.1.10.1 Business Overview
19.1.10.2 Products/Services/Solutions Offered
19.1.10.3 Recent Developments
19.1.10.3.1 Deals
19.1.11 Quest Diagnostics
19.1.11.1 Business Overview
19.1.11.2 Products/Services/Solutions Offered
19.1.11.3 Recent Developments
19.1.11.3.1 Deals
19.1.12 Guardant Health
19.1.12.1 Business Overview
19.1.12.2 Products/Services/Solutions Offered
19.1.12.3 Recent Developments
19.1.12.3.1 Product Launches & Approvals
19.1.13 Icon PLC
19.1.13.1 Business Overview
19.1.13.2 Products/Services/Solutions Offered
19.1.14 Tempus AI, Inc.
19.1.14.1 Business Overview
19.1.14.2 Products/Services/Solutions Offered
19.1.14.3 Recent Developments
19.1.14.3.1 Deals
19.1.14.3.2 Other Developments
19.1.15 Caris Life Sciences, Inc.
19.1.15.1 Business Overview
19.1.15.2 Products/Services/Solutions Offered
19.1.15.3 Recent Developments
19.1.15.3.1 Product Launches & Approvals
19.2 Other Players
19.2.1 the Almac Group
19.2.2 Amoy Diagnostics Co. Ltd.
19.2.3 Arup Laboratories
19.2.4 Abnova Corporation
19.2.5 Invivoscribe, Inc.
19.2.6 Q² Solutions
19.2.7 Creative Biolabs
19.2.8 Pillar Biosciences
19.2.9 Entrogen, Inc.
19.2.10 Biocartis
20 Research Methodology
20.1 Research Data
20.1.1 Secondary Data
20.1.1.1 List of Secondary Sources
20.1.1.2 Key Data From Secondary Sources
20.1.2 Primary Data
20.1.2.1 List of Primary Sources
20.1.2.2 Key Data From Primary Sources
20.1.2.3 Key Industry Insights
20.1.2.4 Breakdown of Primary Interviews
20.2 Market Size Estimation
20.2.1 Total Market Size: Companion Diagnostics Market
20.2.2 Bottom-Up Approach
20.2.2.1 Approach 1: Revenue Estimation of Key Players
20.2.2.2 Approach 2: Study of Annual Reports and Investor Presentations
20.2.2.3 Approach 3: Primary Interviews
20.2.2.4 Growth Forecast
20.2.2.5 Cagr Projections
20.2.3 Top-Down Approach
20.3 Data Triangulation
20.4 Research Assumptions
20.4.1 Study-Related Assumptions
20.5 Study Assumptions
20.5.1 Parametric Assumptions
20.5.2 Growth Rate Assumptions
20.6 Research Limitations
20.7 Risk Assessment
20.1.1 Secondary Data
20.1.1.1 List of Secondary Sources
20.1.1.2 Key Data From Secondary Sources
20.1.2 Primary Data
20.1.2.1 List of Primary Sources
20.1.2.2 Key Data From Primary Sources
20.1.2.3 Key Industry Insights
20.1.2.4 Breakdown of Primary Interviews
20.2 Market Size Estimation
20.2.1 Total Market Size: Companion Diagnostics Market
20.2.2 Bottom-Up Approach
20.2.2.1 Approach 1: Revenue Estimation of Key Players
20.2.2.2 Approach 2: Study of Annual Reports and Investor Presentations
20.2.2.3 Approach 3: Primary Interviews
20.2.2.4 Growth Forecast
20.2.2.5 Cagr Projections
20.2.3 Top-Down Approach
20.3 Data Triangulation
20.4 Research Assumptions
20.4.1 Study-Related Assumptions
20.5 Study Assumptions
20.5.1 Parametric Assumptions
20.5.2 Growth Rate Assumptions
20.6 Research Limitations
20.7 Risk Assessment
21 Appendix
21.1 Discussion Guide
21.2 Knowledgestore: The Subscription Portal
21.3 Customization Options
21.4 Related Reports
21.5 Author Details
21.2 Knowledgestore: The Subscription Portal
21.3 Customization Options
21.4 Related Reports
21.5 Author Details
List of Tables
Table 1 Companion Diagnostics Market: Porter'S Five Forces Analysis
Table 2 GDP Percentage Change (%), by Key Country, 2023-2030
Table 3 North America: Macroeconomic Indicators
Table 4 Europe: Macroeconomic Indicators
Table 5 Asia-Pacific: Macroeconomic Indicators
Table 6 Latin America: Macroeconomic Indicators
Table 7 Middle East & Africa: Macroeconomic Indicators
Table 8 Companion Diagnostics Market: Role of Companies in Ecosystem
Table 9 Average Selling Price Trend of Companion Diagnostics Products, by Key Player, 2024-2026 (USD)
Table 10 Average Selling Price Trend of Companion Diagnostics Products, by Region, 2024-2026 (USD)
Table 11 Average Selling Price Trend of Companion Diagnostics, Technology Type, by Region, 2024-2026 (USD)
Table 12 Import Data For Hs Code 3822-Compliant Products, by Country, 2021-2025 (USD Million)
Table 13 Export Data For Hs Code 3822-Compliant Products, by Country, 2021-2025 (USD Million)
Table 14 Companion Diagnostics Market: Key Conferences & Events, 2026-2027
Table 15 US-Adjusted Reciprocal Tariff Rates
Table 16 Key Patents in Companion Diagnostics Market, 2022-2026
Table 17 Key Companies Implementing AI in Companion Diagnostics
Table 18 Classification of Ivd Devices in Europe
Table 19 Time, Cost, and Complexity of Registration Process in Japan
Table 20 Classification of Ivd Medical Devices in Australia
Table 21 North America: Key Regulatory Bodies, Government Agencies, and Other Organizations
Table 22 Europe: Key Regulatory Bodies, Government Agencies, and Other Organizations
Table 23 Asia-Pacific: Key Regulatory Bodies, Government Agencies, and Other Organizations
Table 24 Latin America: Key Regulatory Bodies, Government Agencies, and Other Organizations
Table 25 Rest of the World: Key Regulatory Bodies, Government Agencies, and Other Organizations
Table 26 Influence of Stakeholders On Buying Process, by Product & Service (%)
Table 27 Key Buying Criteria, by Product & Service
Table 28 Adoption Barriers & Internal Challenges
Table 29 Molecular Infectious Disease Testing Market: Unmet Needs in Various End-Use Industries
Table 30 Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 31 Assays, Kits, and Reagents Offered by Key Players
Table 32 Companion Diagnostics Market For Assays, Kits, and Reagents, by Region, 2024-2031 (USD Million)
Table 33 North America: Companion Diagnostics Market For Assays, Kits, and Reagents, by Country, 2024-2031 (USD Million)
Table 34 Europe: Companion Diagnostics Market For Assays, Kits, and Reagents, by Country, 2024-2031 (USD Million)
Table 35 Asia-Pacific: Companion Diagnostics Market For Assays, Kits, and Reagents, by Country, 2024-2031 (USD Million)
Table 36 Latin America: Companion Diagnostics Market For Assays, Kits, and Reagents, by Country, 2024-2031 (USD Million)
Table 37 Middle East & Africa: Companion Diagnostics Market For Assays, Kits, and Reagents, by Region, 2024-2031 (USD Million)
Table 38 Instruments/Systems Offered by Key Players
Table 39 Companion Diagnostics Market For Instruments/Systems, by Region, 2024-2031 (USD Million)
Table 40 North America: Companion Diagnostics Market For Instruments/Systems, by Country, 2024-2031 (USD Million)
Table 41 Europe: Companion Diagnostics Market For Instruments/Systems, by Country, 2024-2031 (USD Million)
Table 42 Asia-Pacific: Companion Diagnostics Market For Instruments/Systems, by Country, 2024-2031 (USD Million)
Table 43 Latin America: Companion Diagnostics Market For Instruments/Systems, by Country, 2024-2031 (USD Million)
Table 44 Middle East & Africa: Companion Diagnostics Market For Instruments/Systems, by Region, 2024-2031 (USD Million)
Table 45 Key Software & Services Available in Market
Table 46 Companion Diagnostics Market For Software & Services, by Region, 2024-2031 (USD Million)
Table 47 North America: Companion Diagnostics Market For Software & Services, by Country, 2024-2031 (USD Million)
Table 48 Europe: Companion Diagnostics Market For Software & Services, by Country, 2024-2031 (USD Million)
Table 49 Asia-Pacific: Companion Diagnostics Market For Software & Services, by Country, 2024-2031 (USD Million)
Table 50 Latin America: Companion Diagnostics Market For Software & Services, by Country, 2024-2031 (USD Million)
Table 51 Middle East & Africa: Companion Diagnostics Market For Software & Services, by Region, 2024-2031 (USD Million)
Table 52 Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 53 Examples of Fda-Approved Tissue-Based Companion Diagnostics Products
Table 54 Companion Diagnostics Market For Tissue Samples, by Region, 2024-2031 (USD Million)
Table 55 North America: Companion Diagnostics Market For Tissue Samples, by Country, 2024-2031 (USD Million)
Table 56 Europe: Companion Diagnostics Market For Tissue Samples, by Country, 2024-2031 (USD Million)
Table 57 Asia-Pacific: Companion Diagnostics Market For Tissue Samples, by Country, 2024-2031 (USD Million)
Table 58 Latin America: Companion Diagnostics Market For Tissue Samples, by Country, 2024-2031 (USD Million)
Table 59 Middle East & Africa: Companion Diagnostics Market For Tissue Samples, by Region, 2024-2031 (USD Million)
Table 60 Examples of Fda-Approved Blood-Based Companion Diagnostics Products
Table 61 Companion Diagnostics Market For Blood Samples, by Region, 2024-2031 (USD Million)
Table 62 North America: Companion Diagnostics Market For Blood Samples, by Country, 2024-2031 (USD Million)
Table 63 Europe: Companion Diagnostics Market For Blood Samples, by Country, 2024-2031 (USD Million)
Table 64 Asia-Pacific: Companion Diagnostics Market For Blood Samples, by Country, 2024-2031 (USD Million)
Table 65 Latin America: Companion Diagnostics Market For Blood Samples, by Country, 2024-2031 (USD Million)
Table 66 Middle East & Africa: Companion Diagnostics Market For Blood Samples, by Region, 2024-2031 (USD Million)
Table 67 Examples of Companion Diagnostics Products For Other Sample Types
Table 68 Companion Diagnostics Market For Other Sample Types, by Region, 2024-2031 (USD Million)
Table 69 North America: Companion Diagnostics Market For Other Sample Types, by Country, 2024-2031 (USD Million)
Table 70 Europe: Companion Diagnostics Market For Other Sample Types, by Country, 2024-2031 (USD Million)
Table 71 Asia-Pacific: Companion Diagnostics Market For Other Sample Types, by Country, 2024-2031 (USD Million)
Table 72 Latin America: Companion Diagnostics Market For Other Sample Types, by Country, 2024-2031 (USD Million)
Table 73 Middle East & Africa: Companion Diagnostics Market For Other Sample Types, by Region, 2024-2031 (USD Million)
Table 74 Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 75 Comparison of Tissue Sequencing Platforms For Detection of Ras/Braf Mutation
Table 76 Pcr Tests/Kits Offered by Key Players
Table 77 Companion Diagnostics Market For Pcr, by Region, 2024-2031 (USD Million)
Table 78 North America: Companion Diagnostics Market For Pcr, by Country, 2024-2031 (USD Million)
Table 79 Europe: Companion Diagnostics Market For Pcr, by Country, 2024-2031 (USD Million)
Table 80 Asia-Pacific: Companion Diagnostics Market For Pcr, by Country, 2024-2031 (USD Million)
Table 81 Latin America: Companion Diagnostics Market For Pcr, by Country, 2024-2031 (USD Million)
Table 82 Middle East & Africa: Companion Diagnostics Market For Pcr, by Region, 2024-2031 (USD Million)
Table 83 Ish Tests/Kits Offered by Key Players
Table 84 Companion Diagnostics Market For Ish, by Region, 2024-2031 (USD Million)
Table 85 North America: Companion Diagnostics Market For Ish, by Country, 2024-2031 (USD Million)
Table 86 Europe: Companion Diagnostics Market For Ish, by Country, 2024-2031 (USD Million)
Table 87 Asia-Pacific: Companion Diagnostics Market For Ish, by Country, 2024-2031 (USD Million)
Table 88 Latin America: Companion Diagnostics Market For Ish, by Country, 2024-2031 (USD Million)
Table 89 Middle East & Africa: Companion Diagnostics Market For Ish, by Region, 2024-2031 (USD Million)
Table 90 Ngs Tests/Kits Offered by Key Players
Table 91 Companion Diagnostics Market For Ngs, by Region, 2024-2031 (USD Million)
Table 92 North America: Companion Diagnostics Market For Ngs, by Country, 2024-2031 (USD Million)
Table 93 Europe: Companion Diagnostics Market For Ngs, by Country, 2024-2031 (USD Million)
Table 94 Asia-Pacific: Companion Diagnostics Market For Ngs, by Country, 2024-2031 (USD Million)
Table 95 Latin America: Companion Diagnostics Market For Ngs, by Country, 2024-2031 (USD Million)
Table 96 Middle East & Africa: Companion Diagnostics Market For Ngs, by Region, 2024-2031 (USD Million)
Table 97 Ihc Tests/Kits Offered by Key Players
Table 98 Companion Diagnostics Market For Ihc, by Region, 2024-2031 (USD Million)
Table 99 North America: Companion Diagnostics Market For Ihc, by Country, 2024-2031 (USD Million)
Table 100 Europe: Companion Diagnostics Market For Ihc, by Country, 2024-2031 (USD Million)
Table 101 Asia-Pacific: Companion Diagnostics Market For Ihc, by Country, 2024-2031 (USD Million)
Table 102 Latin America: Companion Diagnostics Market For Ihc, by Country, 2024-2031 (USD Million)
Table 103 Middle East & Africa: Companion Diagnostics Market For Ihc, by Region, 2024-2031 (USD Million)
Table 104 Companion Diagnostics Market For Other Technologies, by Region, 2024-2031 (USD Million)
Table 105 North America: Companion Diagnostics Market For Other Technologies, by Country, 2024-2031 (USD Million)
Table 106 Europe: Companion Diagnostics Market For Other Technologies, by Country, 2024-2031 (USD Million)
Table 107 Asia-Pacific: Companion Diagnostics Market For Other Technologies, by Country, 2024-2031 (USD Million)
Table 108 Latin America: Companion Diagnostics Market For Other Technologies, by Country, 2024-2031 (USD Million)
Table 109 Middle East & Africa: Companion Diagnostics Market For Other Technologies, by Region, 2024-2031 (USD Million)
Table 110 Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 111 Estimated Number of Cancer Cases, by Region, 2025 Vs. 2040
Table 112 Companion Diagnostics Market For Cancer, by Region, 2024-2031 (USD Million)
Table 113 North America: Companion Diagnostics Market For Cancer, by Country, 2024-2031 (USD Million)
Table 114 Europe: Companion Diagnostics Market For Cancer, by Country, 2024-2031 (USD Million)
Table 115 Asia-Pacific: Companion Diagnostics Market For Cancer, by Country, 2024-2031 (USD Million)
Table 116 Latin America: Companion Diagnostics Market For Cancer, by Country, 2024-2031 (USD Million)
Table 117 Middle East & Africa: Companion Diagnostics Market For Cancer, by Region, 2024-2031 (USD Million)
Table 118 Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 119 Companion Diagnostics Market For Lung Cancer, by Region, 2024-2031 (USD Million)
Table 120 North America: Companion Diagnostics Market For Lung Cancer, by Country, 2024-2031 (USD Million)
Table 121 Europe: Companion Diagnostics Market For Lung Cancer, by Country, 2024-2031 (USD Million)
Table 122 Asia-Pacific: Companion Diagnostics Market For Lung Cancer, by Country, 2024-2031 (USD Million)
Table 123 Latin America: Companion Diagnostics Market For Lung Cancer, by Country, 2024-2031 (USD Million)
Table 124 Middle East & Africa: Companion Diagnostics Market For Lung Cancer, by Region, 2024-2031 (USD Million)
Table 125 Breast Cancer Testing Products Offered by Key Players
Table 126 Companion Diagnostics Market For Breast Cancer, by Region, 2024-2031 (USD Million)
Table 127 North America: Companion Diagnostics Market For Breast Cancer, by Country, 2024-2031 (USD Million)
Table 128 Europe: Companion Diagnostics Market For Breast Cancer, by Country, 2024-2031 (USD Million)
Table 129 Asia-Pacific: Companion Diagnostics Market For Breast Cancer, by Country, 2024-2031 (USD Million)
Table 130 Latin America: Companion Diagnostics Market For Breast Cancer, by Country, 2024-2031 (USD Million)
Table 131 Middle East & Africa: Companion Diagnostics Market For Breast Cancer, by Region, 2024-2031 (USD Million)
Table 132 Companion Diagnostics Market For Leukemia & Lymphoma, by Region, 2024-2031 (USD Million)
Table 133 North America: Companion Diagnostics Market For Leukemia & Lymphoma, by Country, 2024-2031 (USD Million)
Table 134 Europe: Companion Diagnostics Market For Leukemia & Lymphoma, by Country, 2024-2031 (USD Million)
Table 135 Asia-Pacific: Companion Diagnostics Market For Leukemia & Lymphoma, by Country, 2024-2031 (USD Million)
Table 136 Latin America: Companion Diagnostics Market For Leukemia & Lymphoma, by Country, 2024-2031 (USD Million)
Table 137 Middle East & Africa: Companion Diagnostics Market For Leukemia & Lymphoma, by Region, 2024-2031 (USD Million)
Table 138 Companion Diagnostics Market For Colorectal Cancer, by Region, 2024-2031 (USD Million)
Table 139 North America: Companion Diagnostics Market For Colorectal Cancer, by Country, 2024-2031 (USD Million)
Table 140 Europe: Companion Diagnostics Market For Colorectal Cancer, by Country, 2024-2031 (USD Million)
Table 141 Asia-Pacific: Companion Diagnostics Market For Colorectal Cancer, by Country, 2024-2031 (USD Million)
Table 142 Latin America: Companion Diagnostics Market For Colorectal Cancer, by Country, 2024-2031 (USD Million)
Table 143 Middle East & Africa: Companion Diagnostics Market For Colorectal Cancer, by Region, 2024-2031 (USD Million)
Table 144 Companion Diagnostics Market For Melanoma, by Region, 2024-2031 (USD Million)
Table 145 North America: Companion Diagnostics Market For Melanoma, by Country, 2024-2031 (USD Million)
Table 146 Europe: Companion Diagnostics Market For Melanoma, by Country, 2024-2031 (USD Million)
Table 147 Asia-Pacific: Companion Diagnostics Market For Melanoma, by Country, 2024-2031 (USD Million)
Table 148 Latin America: Companion Diagnostics Market For Melanoma, by Country, 2024-2031 (USD Million)
Table 149 Middle East & Africa: Companion Diagnostics Market For Melanoma, by Region, 2024-2031 (USD Million)
Table 150 Companion Diagnostics Market For Other Cancers, by Region, 2024-2031 (USD Million)
Table 151 North America: Companion Diagnostics Market For Other Cancers, by Country, 2024-2031 (USD Million)
Table 152 Europe: Companion Diagnostics Market For Other Cancers, by Country, 2024-2031 (USD Million)
Table 153 Asia-Pacific: Companion Diagnostics Market For Other Cancers, by Country, 2024-2031 (USD Million)
Table 154 Latin America: Companion Diagnostics Market For Other Cancers, by Country, 2024-2031 (USD Million)
Table 155 Middle East & Africa: Companion Diagnostics Market For Other Cancers, by Region, 2024-2031 (USD Million)
Table 156 Companion Diagnostics Market For Neurological Diseases, by Region, 2024-2031 (USD Million)
Table 157 North America: Companion Diagnostics Market For Neurological Diseases, by Country, 2024-2031 (USD Million)
Table 158 Europe: Companion Diagnostics Market For Neurological Diseases, by Country, 2024-2031 (USD Million)
Table 159 Asia-Pacific: Companion Diagnostics Market For Neurological Diseases, by Country, 2024-2031 (USD Million)
Table 160 Latin America: Companion Diagnostics Market For Neurological Diseases, by Country, 2024-2031 (USD Million)
Table 161 Middle East & Africa: Companion Diagnostics Market For Neurological Diseases, by Region, 2024-2031 (USD Million)
Table 162 Companion Diagnostics Market For Cardiovascular Diseases, by Region, 2024-2031 (USD Million)
Table 163 North America: Companion Diagnostics Market For Cardiovascular Diseases, by Country, 2024-2031 (USD Million)
Table 164 Europe: Companion Diagnostics Market For Cardiovascular Diseases, by Country, 2024-2031 (USD Million)
Table 165 Asia-Pacific: Companion Diagnostics Market For Cardiovascular Diseases, by Country, 2024-2031 (USD Million)
Table 166 Latin America: Companion Diagnostics Market For Cardiovascular Diseases, by Country, 2024-2031 (USD Million)
Table 167 Middle East & Africa: Companion Diagnostics Market For Cardiovascular Diseases, by Region, 2024-2031 (USD Million)
Table 168 Companion Diagnostics Market For Infectious Diseases, by Region, 2024-2031 (USD Million)
Table 169 North America: Companion Diagnostics Market For Infectious Diseases, by Country, 2024-2031 (USD Million)
Table 170 Europe: Companion Diagnostics Market For Infectious Diseases, by Country, 2024-2031 (USD Million)
Table 171 Asia-Pacific: Companion Diagnostics Market For Infectious Diseases, by Country, 2024-2031 (USD Million)
Table 172 Latin America: Companion Diagnostics Market For Infectious Diseases, by Country, 2024-2031 (USD Million)
Table 173 Middle East & Africa: Companion Diagnostics Market For Infectious Diseases, by Region, 2024-2031 (USD Million)
Table 174 Companion Diagnostics Market For Other Indications, by Region, 2024-2031 (USD Million)
Table 175 North America: Companion Diagnostics Market For Other Indications, by Country, 2024-2031 (USD Million)
Table 176 Europe: Companion Diagnostics Market For Other Indications, by Country, 2024-2031 (USD Million)
Table 177 Asia-Pacific: Companion Diagnostics Market For Other Indications, by Country, 2024-2031 (USD Million)
Table 178 Latin America: Companion Diagnostics Market For Other Indications, by Country, 2024-2031 (USD Million)
Table 179 Middle East & Africa: Companion Diagnostics Market For Other Indications, by Region, 2024-2031 (USD Million)
Table 180 Companion Diagnostics Market For Cancer, by Region, 2024-2031 (Number of Tests in Million)
Table 181 Companion Diagnostics, by Application, 2024-2031 (USD Million)
Table 182 Companion Diagnostics Market For Clinical Diagnostics, by Region, 2024-2031 (USD Million)
Table 183 North America: Companion Diagnostics Market For Clinical Diagnostics, by Country, 2024-2031 (USD Million)
Table 184 Europe: Companion Diagnostics Market For Clinical Diagnostics, by Country, 2024-2031 (USD Million)
Table 185 Asia-Pacific: Companion Diagnostics Market For Clinical Diagnostics, by Country, 2024-2031 (USD Million)
Table 186 Latin America: Companion Diagnostics Market For Clinical Diagnostics, by Country, 2024-2031 (USD Million)
Table 187 Middle East & Africa: Companion Diagnostics Market For Clinical Diagnostics, by Region, 2024-2031 (USD Million)
Table 188 Companion Diagnostics Market For Research Use, by Region, 2024-2031 (USD Million)
Table 189 North America: Companion Diagnostics Market For Research Use, by Country, 2024-2031 (USD Million)
Table 190 Europe: Companion Diagnostics Market For Research Use, by Country, 2024-2031 (USD Million)
Table 191 Asia-Pacific: Companion Diagnostics Market For Research Use, by Country, 2024-2031 (USD Million)
Table 192 Latin America: Companion Diagnostics Market For Research Use, by Country, 2024-2031 (USD Million)
Table 193 Middle East & Africa: Companion Diagnostics Market For Research Use, by Region, 2024-2031 (USD Million)
Table 194 Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 195 Companion Diagnostics Market For Pharmaceutical & Biopharmaceutical Companies, by Region, 2024-2031 (USD Million)
Table 196 North America: Companion Diagnostics Market For Pharmaceutical & Biopharmaceutical Companies, by Country, 2024-2031 (USD Million)
Table 197 Europe: Companion Diagnostics Market For Pharmaceutical & Biopharmaceutical Companies, by Country, 2024-2031 (USD Million)
Table 198 Asia-Pacific: Companion Diagnostics Market For Pharmaceutical & Biopharmaceutical Companies, by Country, 2024-2031 (USD Million)
Table 199 Latin America: Companion Diagnostics Market For Pharmaceutical & Biopharmaceutical Companies, by Country, 2024-2031 (USD Million)
Table 200 Middle East & Africa: Companion Diagnostics Market For Pharmaceutical & Biopharmaceutical Companies, by Region, 2024-2031 (USD Million)
Table 201 Companion Diagnostics Market For Reference Laboratories, by Region, 2024-2031 (USD Million)
Table 202 North America: Companion Diagnostics Market For Reference Laboratories, by Country, 2024-2031 (USD Million)
Table 203 Europe: Companion Diagnostics Market For Reference Laboratories, by Country, 2024-2031 (USD Million)
Table 204 Asia-Pacific: Companion Diagnostics Market For Reference Laboratories, by Country, 2024-2031 (USD Million)
Table 205 Latin America: Companion Diagnostics Market For Reference Laboratories, by Country, 2024-2031 (USD Million)
Table 206 Middle East & Africa: Companion Diagnostics Market For Reference Laboratories, by Region, 2024-2031 (USD Million)
Table 207 Companion Diagnostics Market For Contract Research Organizations, by Region, 2024-2031 (USD Million)
Table 208 North America: Companion Diagnostics Market For Contract Research Organizations, by Country, 2024-2031 (USD Million)
Table 209 Europe: Companion Diagnostics Market For Contract Research Organizations, by Country, 2024-2031 (USD Million)
Table 210 Asia-Pacific: Companion Diagnostics Market For Contract Research Organizations, by Country, 2024-2031 (USD Million)
Table 211 Latin America: Companion Diagnostics Market For Contract Research Organizations, by Country, 2024-2031 (USD Million)
Table 212 Middle East & Africa: Companion Diagnostics Market For Contract Research Organizations, by Region, 2024-2031 (USD Million)
Table 213 Companion Diagnostics Market For Other End Users, by Region, 2024-2031 (USD Million)
Table 214 North America: Companion Diagnostics Market For Other End Users, by Country, 2024-2031 (USD Million)
Table 215 Europe: Companion Diagnostics Market For Other End Users, by Country, 2024-2031 (USD Million)
Table 216 Asia-Pacific: Companion Diagnostics Market For Other End Users, by Country, 2024-2031 (USD Million)
Table 217 Latin America: Companion Diagnostics Market For Other End Users, by Country, 2024-2031 (USD Million)
Table 218 Middle East & Africa: Companion Diagnostics Market For Other End Users, by Region, 2024-2031 (USD Million)
Table 219 Companion Diagnostics Market, by Drug Class Associated With Cdx, 2024-2031 (USD Million)
Table 220 Companion Diagnostics Market For Monoclonal Antibodies, by Region, 2024-2031 (USD Million)
Table 221 North America: Companion Diagnostics Market For Monoclonal Antibodies, by Country, 2024-2031 (USD Million)
Table 222 Europe: Companion Diagnostics Market For Monoclonal Antibodies, by Country, 2024-2031 (USD Million)
Table 223 Asia-Pacific: Companion Diagnostics Market For Monoclonal Antibodies, by Country, 2024-2031 (USD Million)
Table 224 Latin America: Companion Diagnostics Market For Monoclonal Antibodies, by Country, 2024-2031 (USD Million)
Table 225 Middle East & Africa: Companion Diagnostics Market For Monoclonal Antibodies, by Region, 2024-2031 (USD Million)
Table 226 Companion Diagnostics Market For Cell & Gene Therapy, by Region, 2024-2031 (USD Million)
Table 227 North America: Companion Diagnostics Market For Cell & Gene Therapy, by Country, 2024-2031 (USD Million)
Table 228 Europe: Companion Diagnostics Market For Cell & Gene Therapy, by Country, 2024-2031 (USD Million)
Table 229 Asia-Pacific: Companion Diagnostics Market For Cell & Gene Therapy, by Country, 2024-2031 (USD Million)
Table 230 Latin America: Companion Diagnostics Market For Cell & Gene Therapy, by Country, 2024-2031 (USD Million)
Table 231 Middle East & Africa: Companion Diagnostics Market For Cell & Gene Therapy, by Country, 2024-2031 (USD Million)
Table 232 Companion Diagnostics Market, by Region, 2024-2031 (USD Million)
Table 233 North America: Macroeconomic Indicators
Table 234 North America: Companion Diagnostics Market, by Country, 2024-2031 (USD Million)
Table 235 North America: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 236 North America: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 237 North America: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 238 North America: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 239 North America: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 240 North America: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 241 North America: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 242 North America: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 243 US: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 244 US: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 245 US: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 246 US: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 247 US: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 248 US: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 249 US: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 250 US: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 251 Canada: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 252 Canada: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 253 Canada: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 254 Canada: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 255 Canada: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 256 Canada: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 257 Canada: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 258 Canada: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 259 Europe: Macroeconomic Indicators
Table 260 Europe: Companion Diagnostics Market, by Country, 2024-2031 (USD Million)
Table 261 Europe: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 262 Europe: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 263 Europe: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 264 Europe: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 265 Europe: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 266 Europe: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 267 Europe: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 268 Europe: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 269 Germany: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 270 Germany: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 271 Germany: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 272 Germany: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 273 Germany: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 274 Germany: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 275 Germany: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 276 Germany: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 277 UK: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 278 UK: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 279 UK: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 280 UK: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 281 UK: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 282 UK: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 283 UK: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 284 UK: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 285 France: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 286 France: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 287 France: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 288 France: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 289 France: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 290 France: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 291 France: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 292 France: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 293 Italy: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 294 Italy: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 295 Italy: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 296 Italy: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 297 Italy: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 298 Italy: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 299 Italy: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 300 Italy: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 301 Switzerland: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 302 Switzerland: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 303 Switzerland: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 304 Switzerland: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 305 Switzerland: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 306 Switzerland: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 307 Switzerland: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 308 Switzerland: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 309 Spain: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 310 Spain: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 311 Spain: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 312 Spain: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 313 Spain: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 314 Spain: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 315 Spain: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 316 Spain: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 317 Rest of Europe: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 318 Rest of Europe: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 319 Rest of Europe: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 320 Rest of Europe: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 321 Rest of Europe: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 322 Rest of Europe: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 323 Rest of Europe: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 324 Rest of Europe: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 325 Asia-Pacific: Macroeconomic Indicators
Table 326 Asia-Pacific: Companion Diagnostics Market, by Country, 2024-2031 (USD Million)
Table 327 Asia-Pacific: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 328 Asia-Pacific: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 329 Asia-Pacific: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 330 Asia-Pacific: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 331 Asia-Pacific: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 332 Asia-Pacific: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 333 Asia-Pacific: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 334 Asia-Pacific: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 335 China: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 336 China: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 337 China: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 338 China: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 339 China: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 340 China: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 341 China: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 342 China: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 343 Japan: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 344 Japan: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 345 Japan: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 346 Japan: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 347 Japan: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 348 Japan: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 349 Japan: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 350 Japan: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 351 India: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 352 India: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 353 India: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 354 India: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 355 India: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 356 India: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 357 India: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 358 India: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 359 South Korea: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 360 South Korea: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 361 South Korea: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 362 South Korea: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 363 South Korea: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 364 South Korea: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 365 South Korea: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 366 South Korea: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 367 Australia: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 368 Australia: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 369 Australia: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 370 Australia: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 371 Australia: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 372 Australia: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 373 Australia: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 374 Australia: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 375 Rest of Asia-Pacific: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 376 Rest of Asia-Pacific: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 377 Rest of Asia-Pacific: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 378 Rest of Asia-Pacific: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 379 Rest of Asia-Pacific: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 380 Rest of Asia-Pacific: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 381 Rest of Asia-Pacific: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 382 Rest of Asia-Pacific: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 383 Latin America: Macroeconomic Indicators
Table 384 Latin America: Companion Diagnostics Market, by Country, 2024-2031 (USD Million)
Table 385 Latin America: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 386 Latin America: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 387 Latin America: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 388 Latin America: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 389 Latin America: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 390 Latin America: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 391 Latin America: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 392 Latin America: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 393 Brazil: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 394 Brazil: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 395 Brazil: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 396 Brazil: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 397 Brazil: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 398 Brazil: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 399 Brazil: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 400 Brazil: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 401 Mexico: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 402 Mexico: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 403 Mexico: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 404 Mexico: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 405 Mexico: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 406 Mexico: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 407 Mexico: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 408 Mexico: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 409 Rest of Latin America: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 410 Rest of Latin America: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 411 Rest of Latin America: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 412 Rest of Latin America: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 413 Rest of Latin America: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 414 Rest of Latin America: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 415 Rest of Latin America: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 416 Rest of Latin America: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 417 Middle East & Africa: Companion Diagnostics Market, by Region, 2024-2031 (USD Million)
Table 418 Middle East & Africa: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 419 Middle East & Africa: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 420 Middle East & Africa: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 421 Middle East & Africa: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 422 Middle East & Africa: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 423 Middle East & Africa: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 424 Middle East & Africa: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 425 Middle East & Africa: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 426 GCC Countries: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 427 GCC Countries: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 428 GCC Countries: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 429 GCC Countries: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 430 GCC Countries: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 431 GCC Countries: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 432 GCC Countries: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 433 GCC Countries: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 434 Rest of Middle East & Africa: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 435 Rest of Middle East & Africa: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 436 Rest of Middle East & Africa: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 437 Rest of Middle East & Africa: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 438 Rest of Middle East & Africa: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 439 Rest of Middle East & Africa: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 440 Rest of Middle East & Africa: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 441 Rest of Middle East & Africa: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 442 Overview of Strategies Deployed by Key Companies in Companion Diagnostics Market, January 2023-May 2026
Table 443 Companion Diagnostics Market: Degree of Competition
Table 444 Companion Diagnostics Market: Region Footprint
Table 445 Companion Diagnostics Market: Product & Service Footprint
Table 446 Companion Diagnostics Market: Indication Footprint
Table 447 Companion Diagnostics Market: Technology Footprint
Table 448 Companion Diagnostics Market: Detailed List of Key Startups/SMEs
Table 449 Companion Diagnostics Market: Competitive Benchmarking of Startups/SMEs (1/2)
Table 450 Companion Diagnostics Market: Competitive Benchmarking of Startups/SMEs (2/2)
Table 451 Companion Diagnostics Market: Product Launches & Approvals, January 2023-April 2026
Table 452 Companion Diagnostics Market: Deals, January 2023-May 2026
Table 453 Companion Diagnostics Market: Expansions, January 2023-May 2026
Table 454 Companion Diagnostics Market: Other Developments, January 2023-May 2026
Table 455 F. Hoffmann-La Roche Ltd.: Company Overview
Table 456 F. Hoffmann-La Roche Ltd.: Products/Services/Solutions Offered
Table 457 F. Hoffmann-La Roche Ltd.: Product Launches & Approvals, January 2023-May 2026
Table 458 F. Hoffmann-La Roche Ltd.: Deals, January 2023-April 2026
Table 459 F. Hoffmann-La Roche Ltd.: Expansions, January 2023-April 2026
Table 460 Agilent Technologies, Inc.: Company Overview
Table 461 Agilent Technologies, Inc.: Products/Services/Solutions Offered
Table 462 Agilent Technologies, Inc.: Product Launches & Approvals, January 2023-May 2026
Table 463 Agilent Technologies, Inc.: Deals, January 2023-April 2026
Table 464 Qiagen: Company Overview
Table 465 Qiagen: Products/Services/Solutions Offered
Table 466 Qiagen: Product Launches and Approvals, January 2023-May 2026
Table 467 Qiagen: Deals, January 2023-May 2026
Table 468 Qiagen: Expansions, January 2023-May 2026
Table 469 Thermo Fisher Scientific Inc.: Company Overview
Table 470 Thermo Fisher Scientific Inc.: Products/Services/Solutions Offered
Table 471 Thermo Fisher Scientific Inc.: Product Launches, January 2023-April 2026
Table 472 Thermo Fisher Scientific Inc.: Deals, January 2023-April 2026
Table 473 Abbott: Company Overview
Table 474 Abbott: Products/Services/Solutions Offered
Table 475 Abbott: Product Approvals, January 2023-April 2026
Table 476 Abbott: Deals, January 2023-April 2026
Table 477 Danaher: Company Overview
Table 478 Danaher: Products/Services/Solutions Offered
Table 479 Danaher: Product Approvals, January 2023-April 2026
Table 480 Danaher: Deals, January 2023-April 2026
Table 481 Illumina, Inc.: Company Overview
Table 482 Illumina, Inc.: Products/Services/Solutions Offered
Table 483 Illumina, Inc.: Product Launches & Approvals, January 2023-May 2026
Table 484 Illumina, Inc.: Deals, January 2023-April 2026
Table 485 Biomérieux: Company Overview
Table 486 Biomérieux: Products/Services/Solutions Offered
Table 487 Biomérieux: Deals, January 2023-April 2026
Table 488 Myriad Genetics, Inc.: Company Overview
Table 489 Myriad Genetics, Inc.: Products/Services/Solutions Offered
Table 490 Myriad Genetics, Inc.: Product Launches & Approvals, January 2023-May 2026
Table 491 Myriad Genetics, Inc.: Deals, January 2023-April 2026
Table 492 Sysmex Corporation: Company Overview
Table 493 Sysmex Corporation: Products/Services/Solutions Offered
Table 494 Sysmex Corporation: Deals, January 2023-May 2026
Table 495 Quest Diagnostics: Company Overview
Table 496 Quest Diagnostics: Products/Services/Solutions Offered
Table 497 Quest Diagnostics: Deals, January 2022-December 2025
Table 498 Guardant Health: Company Overview
Table 499 Guardant Health: Products/Services/Solutions Offered
Table 500 Guardant Health: Product Launches & Approvals, January 2023-May 2026
Table 501 Guardant Health: Deals, January 2023-May 2026
Table 502 Icon PLC: Company Overview
Table 503 Icon PLC: Services/Products/Services/Solutions Offered
Table 504 Tempus AI, Inc.: Company Overview
Table 505 Tempus AI, Inc.: Products/Services/Solutions Offered
Table 506 Tempus AI, Inc.: Deals, January 2023-April 2026
Table 507 Tempus AI, Inc.: Other Developments, January 2023-May 2026
Table 508 Caris Life Sciences, Inc.: Company Overview
Table 509 Caris Life Sciences, Inc.: Products/Services/Solutions Offered
Table 510 Caris Life Sciences, Inc.: Product Launches & Approvals, January 2023-May 2026
Table 511 Companion Diagnostics Market: Risk Assessment
Table 2 GDP Percentage Change (%), by Key Country, 2023-2030
Table 3 North America: Macroeconomic Indicators
Table 4 Europe: Macroeconomic Indicators
Table 5 Asia-Pacific: Macroeconomic Indicators
Table 6 Latin America: Macroeconomic Indicators
Table 7 Middle East & Africa: Macroeconomic Indicators
Table 8 Companion Diagnostics Market: Role of Companies in Ecosystem
Table 9 Average Selling Price Trend of Companion Diagnostics Products, by Key Player, 2024-2026 (USD)
Table 10 Average Selling Price Trend of Companion Diagnostics Products, by Region, 2024-2026 (USD)
Table 11 Average Selling Price Trend of Companion Diagnostics, Technology Type, by Region, 2024-2026 (USD)
Table 12 Import Data For Hs Code 3822-Compliant Products, by Country, 2021-2025 (USD Million)
Table 13 Export Data For Hs Code 3822-Compliant Products, by Country, 2021-2025 (USD Million)
Table 14 Companion Diagnostics Market: Key Conferences & Events, 2026-2027
Table 15 US-Adjusted Reciprocal Tariff Rates
Table 16 Key Patents in Companion Diagnostics Market, 2022-2026
Table 17 Key Companies Implementing AI in Companion Diagnostics
Table 18 Classification of Ivd Devices in Europe
Table 19 Time, Cost, and Complexity of Registration Process in Japan
Table 20 Classification of Ivd Medical Devices in Australia
Table 21 North America: Key Regulatory Bodies, Government Agencies, and Other Organizations
Table 22 Europe: Key Regulatory Bodies, Government Agencies, and Other Organizations
Table 23 Asia-Pacific: Key Regulatory Bodies, Government Agencies, and Other Organizations
Table 24 Latin America: Key Regulatory Bodies, Government Agencies, and Other Organizations
Table 25 Rest of the World: Key Regulatory Bodies, Government Agencies, and Other Organizations
Table 26 Influence of Stakeholders On Buying Process, by Product & Service (%)
Table 27 Key Buying Criteria, by Product & Service
Table 28 Adoption Barriers & Internal Challenges
Table 29 Molecular Infectious Disease Testing Market: Unmet Needs in Various End-Use Industries
Table 30 Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 31 Assays, Kits, and Reagents Offered by Key Players
Table 32 Companion Diagnostics Market For Assays, Kits, and Reagents, by Region, 2024-2031 (USD Million)
Table 33 North America: Companion Diagnostics Market For Assays, Kits, and Reagents, by Country, 2024-2031 (USD Million)
Table 34 Europe: Companion Diagnostics Market For Assays, Kits, and Reagents, by Country, 2024-2031 (USD Million)
Table 35 Asia-Pacific: Companion Diagnostics Market For Assays, Kits, and Reagents, by Country, 2024-2031 (USD Million)
Table 36 Latin America: Companion Diagnostics Market For Assays, Kits, and Reagents, by Country, 2024-2031 (USD Million)
Table 37 Middle East & Africa: Companion Diagnostics Market For Assays, Kits, and Reagents, by Region, 2024-2031 (USD Million)
Table 38 Instruments/Systems Offered by Key Players
Table 39 Companion Diagnostics Market For Instruments/Systems, by Region, 2024-2031 (USD Million)
Table 40 North America: Companion Diagnostics Market For Instruments/Systems, by Country, 2024-2031 (USD Million)
Table 41 Europe: Companion Diagnostics Market For Instruments/Systems, by Country, 2024-2031 (USD Million)
Table 42 Asia-Pacific: Companion Diagnostics Market For Instruments/Systems, by Country, 2024-2031 (USD Million)
Table 43 Latin America: Companion Diagnostics Market For Instruments/Systems, by Country, 2024-2031 (USD Million)
Table 44 Middle East & Africa: Companion Diagnostics Market For Instruments/Systems, by Region, 2024-2031 (USD Million)
Table 45 Key Software & Services Available in Market
Table 46 Companion Diagnostics Market For Software & Services, by Region, 2024-2031 (USD Million)
Table 47 North America: Companion Diagnostics Market For Software & Services, by Country, 2024-2031 (USD Million)
Table 48 Europe: Companion Diagnostics Market For Software & Services, by Country, 2024-2031 (USD Million)
Table 49 Asia-Pacific: Companion Diagnostics Market For Software & Services, by Country, 2024-2031 (USD Million)
Table 50 Latin America: Companion Diagnostics Market For Software & Services, by Country, 2024-2031 (USD Million)
Table 51 Middle East & Africa: Companion Diagnostics Market For Software & Services, by Region, 2024-2031 (USD Million)
Table 52 Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 53 Examples of Fda-Approved Tissue-Based Companion Diagnostics Products
Table 54 Companion Diagnostics Market For Tissue Samples, by Region, 2024-2031 (USD Million)
Table 55 North America: Companion Diagnostics Market For Tissue Samples, by Country, 2024-2031 (USD Million)
Table 56 Europe: Companion Diagnostics Market For Tissue Samples, by Country, 2024-2031 (USD Million)
Table 57 Asia-Pacific: Companion Diagnostics Market For Tissue Samples, by Country, 2024-2031 (USD Million)
Table 58 Latin America: Companion Diagnostics Market For Tissue Samples, by Country, 2024-2031 (USD Million)
Table 59 Middle East & Africa: Companion Diagnostics Market For Tissue Samples, by Region, 2024-2031 (USD Million)
Table 60 Examples of Fda-Approved Blood-Based Companion Diagnostics Products
Table 61 Companion Diagnostics Market For Blood Samples, by Region, 2024-2031 (USD Million)
Table 62 North America: Companion Diagnostics Market For Blood Samples, by Country, 2024-2031 (USD Million)
Table 63 Europe: Companion Diagnostics Market For Blood Samples, by Country, 2024-2031 (USD Million)
Table 64 Asia-Pacific: Companion Diagnostics Market For Blood Samples, by Country, 2024-2031 (USD Million)
Table 65 Latin America: Companion Diagnostics Market For Blood Samples, by Country, 2024-2031 (USD Million)
Table 66 Middle East & Africa: Companion Diagnostics Market For Blood Samples, by Region, 2024-2031 (USD Million)
Table 67 Examples of Companion Diagnostics Products For Other Sample Types
Table 68 Companion Diagnostics Market For Other Sample Types, by Region, 2024-2031 (USD Million)
Table 69 North America: Companion Diagnostics Market For Other Sample Types, by Country, 2024-2031 (USD Million)
Table 70 Europe: Companion Diagnostics Market For Other Sample Types, by Country, 2024-2031 (USD Million)
Table 71 Asia-Pacific: Companion Diagnostics Market For Other Sample Types, by Country, 2024-2031 (USD Million)
Table 72 Latin America: Companion Diagnostics Market For Other Sample Types, by Country, 2024-2031 (USD Million)
Table 73 Middle East & Africa: Companion Diagnostics Market For Other Sample Types, by Region, 2024-2031 (USD Million)
Table 74 Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 75 Comparison of Tissue Sequencing Platforms For Detection of Ras/Braf Mutation
Table 76 Pcr Tests/Kits Offered by Key Players
Table 77 Companion Diagnostics Market For Pcr, by Region, 2024-2031 (USD Million)
Table 78 North America: Companion Diagnostics Market For Pcr, by Country, 2024-2031 (USD Million)
Table 79 Europe: Companion Diagnostics Market For Pcr, by Country, 2024-2031 (USD Million)
Table 80 Asia-Pacific: Companion Diagnostics Market For Pcr, by Country, 2024-2031 (USD Million)
Table 81 Latin America: Companion Diagnostics Market For Pcr, by Country, 2024-2031 (USD Million)
Table 82 Middle East & Africa: Companion Diagnostics Market For Pcr, by Region, 2024-2031 (USD Million)
Table 83 Ish Tests/Kits Offered by Key Players
Table 84 Companion Diagnostics Market For Ish, by Region, 2024-2031 (USD Million)
Table 85 North America: Companion Diagnostics Market For Ish, by Country, 2024-2031 (USD Million)
Table 86 Europe: Companion Diagnostics Market For Ish, by Country, 2024-2031 (USD Million)
Table 87 Asia-Pacific: Companion Diagnostics Market For Ish, by Country, 2024-2031 (USD Million)
Table 88 Latin America: Companion Diagnostics Market For Ish, by Country, 2024-2031 (USD Million)
Table 89 Middle East & Africa: Companion Diagnostics Market For Ish, by Region, 2024-2031 (USD Million)
Table 90 Ngs Tests/Kits Offered by Key Players
Table 91 Companion Diagnostics Market For Ngs, by Region, 2024-2031 (USD Million)
Table 92 North America: Companion Diagnostics Market For Ngs, by Country, 2024-2031 (USD Million)
Table 93 Europe: Companion Diagnostics Market For Ngs, by Country, 2024-2031 (USD Million)
Table 94 Asia-Pacific: Companion Diagnostics Market For Ngs, by Country, 2024-2031 (USD Million)
Table 95 Latin America: Companion Diagnostics Market For Ngs, by Country, 2024-2031 (USD Million)
Table 96 Middle East & Africa: Companion Diagnostics Market For Ngs, by Region, 2024-2031 (USD Million)
Table 97 Ihc Tests/Kits Offered by Key Players
Table 98 Companion Diagnostics Market For Ihc, by Region, 2024-2031 (USD Million)
Table 99 North America: Companion Diagnostics Market For Ihc, by Country, 2024-2031 (USD Million)
Table 100 Europe: Companion Diagnostics Market For Ihc, by Country, 2024-2031 (USD Million)
Table 101 Asia-Pacific: Companion Diagnostics Market For Ihc, by Country, 2024-2031 (USD Million)
Table 102 Latin America: Companion Diagnostics Market For Ihc, by Country, 2024-2031 (USD Million)
Table 103 Middle East & Africa: Companion Diagnostics Market For Ihc, by Region, 2024-2031 (USD Million)
Table 104 Companion Diagnostics Market For Other Technologies, by Region, 2024-2031 (USD Million)
Table 105 North America: Companion Diagnostics Market For Other Technologies, by Country, 2024-2031 (USD Million)
Table 106 Europe: Companion Diagnostics Market For Other Technologies, by Country, 2024-2031 (USD Million)
Table 107 Asia-Pacific: Companion Diagnostics Market For Other Technologies, by Country, 2024-2031 (USD Million)
Table 108 Latin America: Companion Diagnostics Market For Other Technologies, by Country, 2024-2031 (USD Million)
Table 109 Middle East & Africa: Companion Diagnostics Market For Other Technologies, by Region, 2024-2031 (USD Million)
Table 110 Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 111 Estimated Number of Cancer Cases, by Region, 2025 Vs. 2040
Table 112 Companion Diagnostics Market For Cancer, by Region, 2024-2031 (USD Million)
Table 113 North America: Companion Diagnostics Market For Cancer, by Country, 2024-2031 (USD Million)
Table 114 Europe: Companion Diagnostics Market For Cancer, by Country, 2024-2031 (USD Million)
Table 115 Asia-Pacific: Companion Diagnostics Market For Cancer, by Country, 2024-2031 (USD Million)
Table 116 Latin America: Companion Diagnostics Market For Cancer, by Country, 2024-2031 (USD Million)
Table 117 Middle East & Africa: Companion Diagnostics Market For Cancer, by Region, 2024-2031 (USD Million)
Table 118 Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 119 Companion Diagnostics Market For Lung Cancer, by Region, 2024-2031 (USD Million)
Table 120 North America: Companion Diagnostics Market For Lung Cancer, by Country, 2024-2031 (USD Million)
Table 121 Europe: Companion Diagnostics Market For Lung Cancer, by Country, 2024-2031 (USD Million)
Table 122 Asia-Pacific: Companion Diagnostics Market For Lung Cancer, by Country, 2024-2031 (USD Million)
Table 123 Latin America: Companion Diagnostics Market For Lung Cancer, by Country, 2024-2031 (USD Million)
Table 124 Middle East & Africa: Companion Diagnostics Market For Lung Cancer, by Region, 2024-2031 (USD Million)
Table 125 Breast Cancer Testing Products Offered by Key Players
Table 126 Companion Diagnostics Market For Breast Cancer, by Region, 2024-2031 (USD Million)
Table 127 North America: Companion Diagnostics Market For Breast Cancer, by Country, 2024-2031 (USD Million)
Table 128 Europe: Companion Diagnostics Market For Breast Cancer, by Country, 2024-2031 (USD Million)
Table 129 Asia-Pacific: Companion Diagnostics Market For Breast Cancer, by Country, 2024-2031 (USD Million)
Table 130 Latin America: Companion Diagnostics Market For Breast Cancer, by Country, 2024-2031 (USD Million)
Table 131 Middle East & Africa: Companion Diagnostics Market For Breast Cancer, by Region, 2024-2031 (USD Million)
Table 132 Companion Diagnostics Market For Leukemia & Lymphoma, by Region, 2024-2031 (USD Million)
Table 133 North America: Companion Diagnostics Market For Leukemia & Lymphoma, by Country, 2024-2031 (USD Million)
Table 134 Europe: Companion Diagnostics Market For Leukemia & Lymphoma, by Country, 2024-2031 (USD Million)
Table 135 Asia-Pacific: Companion Diagnostics Market For Leukemia & Lymphoma, by Country, 2024-2031 (USD Million)
Table 136 Latin America: Companion Diagnostics Market For Leukemia & Lymphoma, by Country, 2024-2031 (USD Million)
Table 137 Middle East & Africa: Companion Diagnostics Market For Leukemia & Lymphoma, by Region, 2024-2031 (USD Million)
Table 138 Companion Diagnostics Market For Colorectal Cancer, by Region, 2024-2031 (USD Million)
Table 139 North America: Companion Diagnostics Market For Colorectal Cancer, by Country, 2024-2031 (USD Million)
Table 140 Europe: Companion Diagnostics Market For Colorectal Cancer, by Country, 2024-2031 (USD Million)
Table 141 Asia-Pacific: Companion Diagnostics Market For Colorectal Cancer, by Country, 2024-2031 (USD Million)
Table 142 Latin America: Companion Diagnostics Market For Colorectal Cancer, by Country, 2024-2031 (USD Million)
Table 143 Middle East & Africa: Companion Diagnostics Market For Colorectal Cancer, by Region, 2024-2031 (USD Million)
Table 144 Companion Diagnostics Market For Melanoma, by Region, 2024-2031 (USD Million)
Table 145 North America: Companion Diagnostics Market For Melanoma, by Country, 2024-2031 (USD Million)
Table 146 Europe: Companion Diagnostics Market For Melanoma, by Country, 2024-2031 (USD Million)
Table 147 Asia-Pacific: Companion Diagnostics Market For Melanoma, by Country, 2024-2031 (USD Million)
Table 148 Latin America: Companion Diagnostics Market For Melanoma, by Country, 2024-2031 (USD Million)
Table 149 Middle East & Africa: Companion Diagnostics Market For Melanoma, by Region, 2024-2031 (USD Million)
Table 150 Companion Diagnostics Market For Other Cancers, by Region, 2024-2031 (USD Million)
Table 151 North America: Companion Diagnostics Market For Other Cancers, by Country, 2024-2031 (USD Million)
Table 152 Europe: Companion Diagnostics Market For Other Cancers, by Country, 2024-2031 (USD Million)
Table 153 Asia-Pacific: Companion Diagnostics Market For Other Cancers, by Country, 2024-2031 (USD Million)
Table 154 Latin America: Companion Diagnostics Market For Other Cancers, by Country, 2024-2031 (USD Million)
Table 155 Middle East & Africa: Companion Diagnostics Market For Other Cancers, by Region, 2024-2031 (USD Million)
Table 156 Companion Diagnostics Market For Neurological Diseases, by Region, 2024-2031 (USD Million)
Table 157 North America: Companion Diagnostics Market For Neurological Diseases, by Country, 2024-2031 (USD Million)
Table 158 Europe: Companion Diagnostics Market For Neurological Diseases, by Country, 2024-2031 (USD Million)
Table 159 Asia-Pacific: Companion Diagnostics Market For Neurological Diseases, by Country, 2024-2031 (USD Million)
Table 160 Latin America: Companion Diagnostics Market For Neurological Diseases, by Country, 2024-2031 (USD Million)
Table 161 Middle East & Africa: Companion Diagnostics Market For Neurological Diseases, by Region, 2024-2031 (USD Million)
Table 162 Companion Diagnostics Market For Cardiovascular Diseases, by Region, 2024-2031 (USD Million)
Table 163 North America: Companion Diagnostics Market For Cardiovascular Diseases, by Country, 2024-2031 (USD Million)
Table 164 Europe: Companion Diagnostics Market For Cardiovascular Diseases, by Country, 2024-2031 (USD Million)
Table 165 Asia-Pacific: Companion Diagnostics Market For Cardiovascular Diseases, by Country, 2024-2031 (USD Million)
Table 166 Latin America: Companion Diagnostics Market For Cardiovascular Diseases, by Country, 2024-2031 (USD Million)
Table 167 Middle East & Africa: Companion Diagnostics Market For Cardiovascular Diseases, by Region, 2024-2031 (USD Million)
Table 168 Companion Diagnostics Market For Infectious Diseases, by Region, 2024-2031 (USD Million)
Table 169 North America: Companion Diagnostics Market For Infectious Diseases, by Country, 2024-2031 (USD Million)
Table 170 Europe: Companion Diagnostics Market For Infectious Diseases, by Country, 2024-2031 (USD Million)
Table 171 Asia-Pacific: Companion Diagnostics Market For Infectious Diseases, by Country, 2024-2031 (USD Million)
Table 172 Latin America: Companion Diagnostics Market For Infectious Diseases, by Country, 2024-2031 (USD Million)
Table 173 Middle East & Africa: Companion Diagnostics Market For Infectious Diseases, by Region, 2024-2031 (USD Million)
Table 174 Companion Diagnostics Market For Other Indications, by Region, 2024-2031 (USD Million)
Table 175 North America: Companion Diagnostics Market For Other Indications, by Country, 2024-2031 (USD Million)
Table 176 Europe: Companion Diagnostics Market For Other Indications, by Country, 2024-2031 (USD Million)
Table 177 Asia-Pacific: Companion Diagnostics Market For Other Indications, by Country, 2024-2031 (USD Million)
Table 178 Latin America: Companion Diagnostics Market For Other Indications, by Country, 2024-2031 (USD Million)
Table 179 Middle East & Africa: Companion Diagnostics Market For Other Indications, by Region, 2024-2031 (USD Million)
Table 180 Companion Diagnostics Market For Cancer, by Region, 2024-2031 (Number of Tests in Million)
Table 181 Companion Diagnostics, by Application, 2024-2031 (USD Million)
Table 182 Companion Diagnostics Market For Clinical Diagnostics, by Region, 2024-2031 (USD Million)
Table 183 North America: Companion Diagnostics Market For Clinical Diagnostics, by Country, 2024-2031 (USD Million)
Table 184 Europe: Companion Diagnostics Market For Clinical Diagnostics, by Country, 2024-2031 (USD Million)
Table 185 Asia-Pacific: Companion Diagnostics Market For Clinical Diagnostics, by Country, 2024-2031 (USD Million)
Table 186 Latin America: Companion Diagnostics Market For Clinical Diagnostics, by Country, 2024-2031 (USD Million)
Table 187 Middle East & Africa: Companion Diagnostics Market For Clinical Diagnostics, by Region, 2024-2031 (USD Million)
Table 188 Companion Diagnostics Market For Research Use, by Region, 2024-2031 (USD Million)
Table 189 North America: Companion Diagnostics Market For Research Use, by Country, 2024-2031 (USD Million)
Table 190 Europe: Companion Diagnostics Market For Research Use, by Country, 2024-2031 (USD Million)
Table 191 Asia-Pacific: Companion Diagnostics Market For Research Use, by Country, 2024-2031 (USD Million)
Table 192 Latin America: Companion Diagnostics Market For Research Use, by Country, 2024-2031 (USD Million)
Table 193 Middle East & Africa: Companion Diagnostics Market For Research Use, by Region, 2024-2031 (USD Million)
Table 194 Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 195 Companion Diagnostics Market For Pharmaceutical & Biopharmaceutical Companies, by Region, 2024-2031 (USD Million)
Table 196 North America: Companion Diagnostics Market For Pharmaceutical & Biopharmaceutical Companies, by Country, 2024-2031 (USD Million)
Table 197 Europe: Companion Diagnostics Market For Pharmaceutical & Biopharmaceutical Companies, by Country, 2024-2031 (USD Million)
Table 198 Asia-Pacific: Companion Diagnostics Market For Pharmaceutical & Biopharmaceutical Companies, by Country, 2024-2031 (USD Million)
Table 199 Latin America: Companion Diagnostics Market For Pharmaceutical & Biopharmaceutical Companies, by Country, 2024-2031 (USD Million)
Table 200 Middle East & Africa: Companion Diagnostics Market For Pharmaceutical & Biopharmaceutical Companies, by Region, 2024-2031 (USD Million)
Table 201 Companion Diagnostics Market For Reference Laboratories, by Region, 2024-2031 (USD Million)
Table 202 North America: Companion Diagnostics Market For Reference Laboratories, by Country, 2024-2031 (USD Million)
Table 203 Europe: Companion Diagnostics Market For Reference Laboratories, by Country, 2024-2031 (USD Million)
Table 204 Asia-Pacific: Companion Diagnostics Market For Reference Laboratories, by Country, 2024-2031 (USD Million)
Table 205 Latin America: Companion Diagnostics Market For Reference Laboratories, by Country, 2024-2031 (USD Million)
Table 206 Middle East & Africa: Companion Diagnostics Market For Reference Laboratories, by Region, 2024-2031 (USD Million)
Table 207 Companion Diagnostics Market For Contract Research Organizations, by Region, 2024-2031 (USD Million)
Table 208 North America: Companion Diagnostics Market For Contract Research Organizations, by Country, 2024-2031 (USD Million)
Table 209 Europe: Companion Diagnostics Market For Contract Research Organizations, by Country, 2024-2031 (USD Million)
Table 210 Asia-Pacific: Companion Diagnostics Market For Contract Research Organizations, by Country, 2024-2031 (USD Million)
Table 211 Latin America: Companion Diagnostics Market For Contract Research Organizations, by Country, 2024-2031 (USD Million)
Table 212 Middle East & Africa: Companion Diagnostics Market For Contract Research Organizations, by Region, 2024-2031 (USD Million)
Table 213 Companion Diagnostics Market For Other End Users, by Region, 2024-2031 (USD Million)
Table 214 North America: Companion Diagnostics Market For Other End Users, by Country, 2024-2031 (USD Million)
Table 215 Europe: Companion Diagnostics Market For Other End Users, by Country, 2024-2031 (USD Million)
Table 216 Asia-Pacific: Companion Diagnostics Market For Other End Users, by Country, 2024-2031 (USD Million)
Table 217 Latin America: Companion Diagnostics Market For Other End Users, by Country, 2024-2031 (USD Million)
Table 218 Middle East & Africa: Companion Diagnostics Market For Other End Users, by Region, 2024-2031 (USD Million)
Table 219 Companion Diagnostics Market, by Drug Class Associated With Cdx, 2024-2031 (USD Million)
Table 220 Companion Diagnostics Market For Monoclonal Antibodies, by Region, 2024-2031 (USD Million)
Table 221 North America: Companion Diagnostics Market For Monoclonal Antibodies, by Country, 2024-2031 (USD Million)
Table 222 Europe: Companion Diagnostics Market For Monoclonal Antibodies, by Country, 2024-2031 (USD Million)
Table 223 Asia-Pacific: Companion Diagnostics Market For Monoclonal Antibodies, by Country, 2024-2031 (USD Million)
Table 224 Latin America: Companion Diagnostics Market For Monoclonal Antibodies, by Country, 2024-2031 (USD Million)
Table 225 Middle East & Africa: Companion Diagnostics Market For Monoclonal Antibodies, by Region, 2024-2031 (USD Million)
Table 226 Companion Diagnostics Market For Cell & Gene Therapy, by Region, 2024-2031 (USD Million)
Table 227 North America: Companion Diagnostics Market For Cell & Gene Therapy, by Country, 2024-2031 (USD Million)
Table 228 Europe: Companion Diagnostics Market For Cell & Gene Therapy, by Country, 2024-2031 (USD Million)
Table 229 Asia-Pacific: Companion Diagnostics Market For Cell & Gene Therapy, by Country, 2024-2031 (USD Million)
Table 230 Latin America: Companion Diagnostics Market For Cell & Gene Therapy, by Country, 2024-2031 (USD Million)
Table 231 Middle East & Africa: Companion Diagnostics Market For Cell & Gene Therapy, by Country, 2024-2031 (USD Million)
Table 232 Companion Diagnostics Market, by Region, 2024-2031 (USD Million)
Table 233 North America: Macroeconomic Indicators
Table 234 North America: Companion Diagnostics Market, by Country, 2024-2031 (USD Million)
Table 235 North America: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 236 North America: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 237 North America: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 238 North America: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 239 North America: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 240 North America: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 241 North America: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 242 North America: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 243 US: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 244 US: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 245 US: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 246 US: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 247 US: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 248 US: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 249 US: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 250 US: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 251 Canada: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 252 Canada: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 253 Canada: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 254 Canada: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 255 Canada: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 256 Canada: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 257 Canada: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 258 Canada: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 259 Europe: Macroeconomic Indicators
Table 260 Europe: Companion Diagnostics Market, by Country, 2024-2031 (USD Million)
Table 261 Europe: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 262 Europe: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 263 Europe: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 264 Europe: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 265 Europe: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 266 Europe: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 267 Europe: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 268 Europe: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 269 Germany: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 270 Germany: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 271 Germany: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 272 Germany: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 273 Germany: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 274 Germany: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 275 Germany: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 276 Germany: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 277 UK: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 278 UK: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 279 UK: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 280 UK: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 281 UK: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 282 UK: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 283 UK: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 284 UK: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 285 France: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 286 France: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 287 France: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 288 France: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 289 France: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 290 France: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 291 France: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 292 France: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 293 Italy: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 294 Italy: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 295 Italy: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 296 Italy: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 297 Italy: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 298 Italy: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 299 Italy: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 300 Italy: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 301 Switzerland: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 302 Switzerland: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 303 Switzerland: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 304 Switzerland: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 305 Switzerland: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 306 Switzerland: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 307 Switzerland: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 308 Switzerland: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 309 Spain: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 310 Spain: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 311 Spain: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 312 Spain: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 313 Spain: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 314 Spain: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 315 Spain: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 316 Spain: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 317 Rest of Europe: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 318 Rest of Europe: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 319 Rest of Europe: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 320 Rest of Europe: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 321 Rest of Europe: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 322 Rest of Europe: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 323 Rest of Europe: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 324 Rest of Europe: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 325 Asia-Pacific: Macroeconomic Indicators
Table 326 Asia-Pacific: Companion Diagnostics Market, by Country, 2024-2031 (USD Million)
Table 327 Asia-Pacific: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 328 Asia-Pacific: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 329 Asia-Pacific: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 330 Asia-Pacific: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 331 Asia-Pacific: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 332 Asia-Pacific: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 333 Asia-Pacific: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 334 Asia-Pacific: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 335 China: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 336 China: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 337 China: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 338 China: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 339 China: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 340 China: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 341 China: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 342 China: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 343 Japan: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 344 Japan: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 345 Japan: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 346 Japan: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 347 Japan: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 348 Japan: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 349 Japan: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 350 Japan: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 351 India: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 352 India: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 353 India: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 354 India: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 355 India: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 356 India: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 357 India: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 358 India: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 359 South Korea: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 360 South Korea: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 361 South Korea: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 362 South Korea: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 363 South Korea: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 364 South Korea: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 365 South Korea: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 366 South Korea: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 367 Australia: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 368 Australia: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 369 Australia: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 370 Australia: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 371 Australia: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 372 Australia: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 373 Australia: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 374 Australia: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 375 Rest of Asia-Pacific: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 376 Rest of Asia-Pacific: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 377 Rest of Asia-Pacific: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 378 Rest of Asia-Pacific: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 379 Rest of Asia-Pacific: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 380 Rest of Asia-Pacific: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 381 Rest of Asia-Pacific: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 382 Rest of Asia-Pacific: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 383 Latin America: Macroeconomic Indicators
Table 384 Latin America: Companion Diagnostics Market, by Country, 2024-2031 (USD Million)
Table 385 Latin America: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 386 Latin America: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 387 Latin America: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 388 Latin America: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 389 Latin America: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 390 Latin America: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 391 Latin America: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 392 Latin America: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 393 Brazil: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 394 Brazil: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 395 Brazil: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 396 Brazil: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 397 Brazil: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 398 Brazil: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 399 Brazil: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 400 Brazil: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 401 Mexico: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 402 Mexico: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 403 Mexico: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 404 Mexico: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 405 Mexico: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 406 Mexico: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 407 Mexico: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 408 Mexico: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 409 Rest of Latin America: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 410 Rest of Latin America: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 411 Rest of Latin America: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 412 Rest of Latin America: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 413 Rest of Latin America: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 414 Rest of Latin America: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 415 Rest of Latin America: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 416 Rest of Latin America: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 417 Middle East & Africa: Companion Diagnostics Market, by Region, 2024-2031 (USD Million)
Table 418 Middle East & Africa: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 419 Middle East & Africa: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 420 Middle East & Africa: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 421 Middle East & Africa: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 422 Middle East & Africa: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 423 Middle East & Africa: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 424 Middle East & Africa: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 425 Middle East & Africa: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 426 GCC Countries: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 427 GCC Countries: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 428 GCC Countries: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 429 GCC Countries: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 430 GCC Countries: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 431 GCC Countries: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 432 GCC Countries: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 433 GCC Countries: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 434 Rest of Middle East & Africa: Companion Diagnostics Market, by Product & Service, 2024-2031 (USD Million)
Table 435 Rest of Middle East & Africa: Companion Diagnostics Market, by Technology, 2024-2031 (USD Million)
Table 436 Rest of Middle East & Africa: Companion Diagnostics Market, by Indication, 2024-2031 (USD Million)
Table 437 Rest of Middle East & Africa: Companion Diagnostics Market For Cancer, by Type, 2024-2031 (USD Million)
Table 438 Rest of Middle East & Africa: Companion Diagnostics Market, by Sample Type, 2024-2031 (USD Million)
Table 439 Rest of Middle East & Africa: Companion Diagnostics Market, by End User, 2024-2031 (USD Million)
Table 440 Rest of Middle East & Africa: Companion Diagnostics Market, by Drug Class Associated With Companion Diagnostics, 2024-2031 (USD Million)
Table 441 Rest of Middle East & Africa: Companion Diagnostics Market, by Application, 2024-2031 (USD Million)
Table 442 Overview of Strategies Deployed by Key Companies in Companion Diagnostics Market, January 2023-May 2026
Table 443 Companion Diagnostics Market: Degree of Competition
Table 444 Companion Diagnostics Market: Region Footprint
Table 445 Companion Diagnostics Market: Product & Service Footprint
Table 446 Companion Diagnostics Market: Indication Footprint
Table 447 Companion Diagnostics Market: Technology Footprint
Table 448 Companion Diagnostics Market: Detailed List of Key Startups/SMEs
Table 449 Companion Diagnostics Market: Competitive Benchmarking of Startups/SMEs (1/2)
Table 450 Companion Diagnostics Market: Competitive Benchmarking of Startups/SMEs (2/2)
Table 451 Companion Diagnostics Market: Product Launches & Approvals, January 2023-April 2026
Table 452 Companion Diagnostics Market: Deals, January 2023-May 2026
Table 453 Companion Diagnostics Market: Expansions, January 2023-May 2026
Table 454 Companion Diagnostics Market: Other Developments, January 2023-May 2026
Table 455 F. Hoffmann-La Roche Ltd.: Company Overview
Table 456 F. Hoffmann-La Roche Ltd.: Products/Services/Solutions Offered
Table 457 F. Hoffmann-La Roche Ltd.: Product Launches & Approvals, January 2023-May 2026
Table 458 F. Hoffmann-La Roche Ltd.: Deals, January 2023-April 2026
Table 459 F. Hoffmann-La Roche Ltd.: Expansions, January 2023-April 2026
Table 460 Agilent Technologies, Inc.: Company Overview
Table 461 Agilent Technologies, Inc.: Products/Services/Solutions Offered
Table 462 Agilent Technologies, Inc.: Product Launches & Approvals, January 2023-May 2026
Table 463 Agilent Technologies, Inc.: Deals, January 2023-April 2026
Table 464 Qiagen: Company Overview
Table 465 Qiagen: Products/Services/Solutions Offered
Table 466 Qiagen: Product Launches and Approvals, January 2023-May 2026
Table 467 Qiagen: Deals, January 2023-May 2026
Table 468 Qiagen: Expansions, January 2023-May 2026
Table 469 Thermo Fisher Scientific Inc.: Company Overview
Table 470 Thermo Fisher Scientific Inc.: Products/Services/Solutions Offered
Table 471 Thermo Fisher Scientific Inc.: Product Launches, January 2023-April 2026
Table 472 Thermo Fisher Scientific Inc.: Deals, January 2023-April 2026
Table 473 Abbott: Company Overview
Table 474 Abbott: Products/Services/Solutions Offered
Table 475 Abbott: Product Approvals, January 2023-April 2026
Table 476 Abbott: Deals, January 2023-April 2026
Table 477 Danaher: Company Overview
Table 478 Danaher: Products/Services/Solutions Offered
Table 479 Danaher: Product Approvals, January 2023-April 2026
Table 480 Danaher: Deals, January 2023-April 2026
Table 481 Illumina, Inc.: Company Overview
Table 482 Illumina, Inc.: Products/Services/Solutions Offered
Table 483 Illumina, Inc.: Product Launches & Approvals, January 2023-May 2026
Table 484 Illumina, Inc.: Deals, January 2023-April 2026
Table 485 Biomérieux: Company Overview
Table 486 Biomérieux: Products/Services/Solutions Offered
Table 487 Biomérieux: Deals, January 2023-April 2026
Table 488 Myriad Genetics, Inc.: Company Overview
Table 489 Myriad Genetics, Inc.: Products/Services/Solutions Offered
Table 490 Myriad Genetics, Inc.: Product Launches & Approvals, January 2023-May 2026
Table 491 Myriad Genetics, Inc.: Deals, January 2023-April 2026
Table 492 Sysmex Corporation: Company Overview
Table 493 Sysmex Corporation: Products/Services/Solutions Offered
Table 494 Sysmex Corporation: Deals, January 2023-May 2026
Table 495 Quest Diagnostics: Company Overview
Table 496 Quest Diagnostics: Products/Services/Solutions Offered
Table 497 Quest Diagnostics: Deals, January 2022-December 2025
Table 498 Guardant Health: Company Overview
Table 499 Guardant Health: Products/Services/Solutions Offered
Table 500 Guardant Health: Product Launches & Approvals, January 2023-May 2026
Table 501 Guardant Health: Deals, January 2023-May 2026
Table 502 Icon PLC: Company Overview
Table 503 Icon PLC: Services/Products/Services/Solutions Offered
Table 504 Tempus AI, Inc.: Company Overview
Table 505 Tempus AI, Inc.: Products/Services/Solutions Offered
Table 506 Tempus AI, Inc.: Deals, January 2023-April 2026
Table 507 Tempus AI, Inc.: Other Developments, January 2023-May 2026
Table 508 Caris Life Sciences, Inc.: Company Overview
Table 509 Caris Life Sciences, Inc.: Products/Services/Solutions Offered
Table 510 Caris Life Sciences, Inc.: Product Launches & Approvals, January 2023-May 2026
Table 511 Companion Diagnostics Market: Risk Assessment
List of Figures
Figure 1 Companion Diagnostics Market Segmentation
Figure 2 Key Insights & Market Highlights
Figure 3 Global Companion Diagnostics Market, 2024-2031
Figure 4 Major Strategies Adopted by Key Players in Companion Diagnostics Market, 2023-2025
Figure 5 Disruptive Trends Impacting Growth of Companion Diagnostics Market
Figure 6 High-Growth Segments & Emerging Frontiers in Companion Diagnostics Market, 2025
Figure 7 Asia-Pacific to Register Highest Growth During Forecast Period
Figure 8 Increasing Adoption of Targeted Therapies to Drive Market
Figure 9 Assays, Kits, and Reagents Segment to Dominate Market During Forecast Period
Figure 10 Pcr Segment to Lead Market During Forecast Period
Figure 11 Cancer Segment to Lead Market During Forecast Period
Figure 12 Tissue Sample Segment to Lead Market During Forecast Period
Figure 13 Monoclonal Antibodies Segment to Lead Market During Forecast Period
Figure 14 Clinical Diagnostics Segment to Lead Market During Forecast Period
Figure 15 Asia-Pacific to Register Highest Growth During Forecast Period
Figure 16 Companion Diagnostics Market: Drivers, Restraints, Opportunities, and Challenges
Figure 17 Companion Diagnostics Market: Porter'S Five Forces Analysis
Figure 18 Companion Diagnostics Market: Supply Chain Analysis
Figure 19 Companion Diagnostics Market: Value Chain Analysis
Figure 20 Companion Diagnostics Market: Ecosystem Analysis
Figure 21 Companion Diagnostics Market: Trends & Disruptions Impacting Customers’ Businesses
Figure 22 Deals & Funding Activities in Companion Diagnostics Market
Figure 23 Patent Analysis For Companion Diagnostics Market, January 2016-December 2025
Figure 24 Market Potential of AI in Companion Diagnostics Market
Figure 25 Influence of Stakeholders On Buying Process, by Product & Service
Figure 26 Key Buying Criteria, by Product & Service
Figure 27 North America: Companion Diagnostics Market Snapshot
Figure 28 Asia-Pacific: Companion Diagnostics Market Snapshot
Figure 29 Revenue Analysis of Key Players in Companion Diagnostics Market, 2023-2025 (USD Million)
Figure 30 Companion Diagnostics Market Share Analysis, 2025 (Global)
Figure 31 Companion Diagnostics Market: Company Evaluation Matrix (Key Players), 2025
Figure 32 Companion Diagnostics Market: Company Footprint
Figure 33 Companion Diagnostics Market: Company Evaluation Matrix (Startups/SMEs), 2025
Figure 34 Ev/EBITDA of Key Vendors
Figure 35 Year-To-Date (YTD) Price Total Return and 5-Year Stock Beta of Key Vendors
Figure 36 Companion Diagnostics Market: Brand/Product Comparison For Companion Diagnostics
Figure 37 F. Hoffmann-La Roche Ltd.: Company Snapshot (2025)
Figure 38 Agilent Technologies, Inc.: Company Snapshot (2025)
Figure 39 Qiagen: Company Snapshot (2025)
Figure 40 Thermo Fisher Scientific Inc.: Company Snapshot (2025)
Figure 41 Abbott: Company Snapshot (2025)
Figure 42 Danaher: Company Snapshot (2025)
Figure 43 Illumina, Inc.: Company Snapshot (2025)
Figure 44 Biomérieux: Company Snapshot (2025)
Figure 45 Myriad Genetics, Inc.: Company Snapshot (2025)
Figure 46 Sysmex Corporation: Company Snapshot (2025)
Figure 47 Quest Diagnostics: Company Snapshot (2025)
Figure 48 Guardant Health: Company Snapshot (2025)
Figure 49 Icon PLC: Company Snapshot (2024)
Figure 50 Tempus AI, Inc.: Company Snapshot (2025)
Figure 51 Caris Life Sciences, Inc.: Company Snapshot (2025)
Figure 52 Research Design
Figure 53 Breakdown of Primary Interviews: by Company Type, Designation, and Region
Figure 54 Drivers, Restraints, Opportunities, and Challenges (2025-2030): Impact On Market Growth and Cagr
Figure 55 Top-Down Approach
Figure 56 Data Triangulation
Figure 2 Key Insights & Market Highlights
Figure 3 Global Companion Diagnostics Market, 2024-2031
Figure 4 Major Strategies Adopted by Key Players in Companion Diagnostics Market, 2023-2025
Figure 5 Disruptive Trends Impacting Growth of Companion Diagnostics Market
Figure 6 High-Growth Segments & Emerging Frontiers in Companion Diagnostics Market, 2025
Figure 7 Asia-Pacific to Register Highest Growth During Forecast Period
Figure 8 Increasing Adoption of Targeted Therapies to Drive Market
Figure 9 Assays, Kits, and Reagents Segment to Dominate Market During Forecast Period
Figure 10 Pcr Segment to Lead Market During Forecast Period
Figure 11 Cancer Segment to Lead Market During Forecast Period
Figure 12 Tissue Sample Segment to Lead Market During Forecast Period
Figure 13 Monoclonal Antibodies Segment to Lead Market During Forecast Period
Figure 14 Clinical Diagnostics Segment to Lead Market During Forecast Period
Figure 15 Asia-Pacific to Register Highest Growth During Forecast Period
Figure 16 Companion Diagnostics Market: Drivers, Restraints, Opportunities, and Challenges
Figure 17 Companion Diagnostics Market: Porter'S Five Forces Analysis
Figure 18 Companion Diagnostics Market: Supply Chain Analysis
Figure 19 Companion Diagnostics Market: Value Chain Analysis
Figure 20 Companion Diagnostics Market: Ecosystem Analysis
Figure 21 Companion Diagnostics Market: Trends & Disruptions Impacting Customers’ Businesses
Figure 22 Deals & Funding Activities in Companion Diagnostics Market
Figure 23 Patent Analysis For Companion Diagnostics Market, January 2016-December 2025
Figure 24 Market Potential of AI in Companion Diagnostics Market
Figure 25 Influence of Stakeholders On Buying Process, by Product & Service
Figure 26 Key Buying Criteria, by Product & Service
Figure 27 North America: Companion Diagnostics Market Snapshot
Figure 28 Asia-Pacific: Companion Diagnostics Market Snapshot
Figure 29 Revenue Analysis of Key Players in Companion Diagnostics Market, 2023-2025 (USD Million)
Figure 30 Companion Diagnostics Market Share Analysis, 2025 (Global)
Figure 31 Companion Diagnostics Market: Company Evaluation Matrix (Key Players), 2025
Figure 32 Companion Diagnostics Market: Company Footprint
Figure 33 Companion Diagnostics Market: Company Evaluation Matrix (Startups/SMEs), 2025
Figure 34 Ev/EBITDA of Key Vendors
Figure 35 Year-To-Date (YTD) Price Total Return and 5-Year Stock Beta of Key Vendors
Figure 36 Companion Diagnostics Market: Brand/Product Comparison For Companion Diagnostics
Figure 37 F. Hoffmann-La Roche Ltd.: Company Snapshot (2025)
Figure 38 Agilent Technologies, Inc.: Company Snapshot (2025)
Figure 39 Qiagen: Company Snapshot (2025)
Figure 40 Thermo Fisher Scientific Inc.: Company Snapshot (2025)
Figure 41 Abbott: Company Snapshot (2025)
Figure 42 Danaher: Company Snapshot (2025)
Figure 43 Illumina, Inc.: Company Snapshot (2025)
Figure 44 Biomérieux: Company Snapshot (2025)
Figure 45 Myriad Genetics, Inc.: Company Snapshot (2025)
Figure 46 Sysmex Corporation: Company Snapshot (2025)
Figure 47 Quest Diagnostics: Company Snapshot (2025)
Figure 48 Guardant Health: Company Snapshot (2025)
Figure 49 Icon PLC: Company Snapshot (2024)
Figure 50 Tempus AI, Inc.: Company Snapshot (2025)
Figure 51 Caris Life Sciences, Inc.: Company Snapshot (2025)
Figure 52 Research Design
Figure 53 Breakdown of Primary Interviews: by Company Type, Designation, and Region
Figure 54 Drivers, Restraints, Opportunities, and Challenges (2025-2030): Impact On Market Growth and Cagr
Figure 55 Top-Down Approach
Figure 56 Data Triangulation
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
- Agilent Technologies, Inc
- Qiagen
- Thermo Fisher Scientific Inc.
- Abbott
- Danaher
- Illumina, Inc.
- Biomérieux
- Myriad Genetics, Inc.
- Sysmex Corporation
- Quest Diagnostics
- Guardant Health
- Icon PLC
- Tempus AI, Inc.
- Caris Life Sciences, Inc.
- the Almac Group
- Amoy Diagnostics Co. Ltd.
- Arup Laboratories
- Abnova Corporation
- Invivoscribe, Inc.
- Q² Solutions
- Creative Biolabs
- Pillar Biosciences
- Entrogen, Inc.
- Biocartis
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 349 |
| Published | June 2026 |
| Forecast Period | 2026 - 2031 |
| Estimated Market Value ( USD | $ 6.31 Billion |
| Forecasted Market Value ( USD | $ 11.57 Billion |
| Compound Annual Growth Rate | 13.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
